<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1125" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1125/" /><meta name="ncbi_pagename" content="Junctional Epidermolysis Bullosa - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Junctional Epidermolysis Bullosa - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Junctional Epidermolysis Bullosa" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/12/20" /><meta name="citation_author" content="Ellen G Pfendner" /><meta name="citation_author" content="Anne W Lucky" /><meta name="citation_pmid" content="20301304" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1125/" /><meta name="citation_keywords" content="Collagen alpha-1(XVII) chain" /><meta name="citation_keywords" content="Integrin beta-4" /><meta name="citation_keywords" content="Laminin subunit alpha-3" /><meta name="citation_keywords" content="Laminin subunit beta-3" /><meta name="citation_keywords" content="Laminin subunit gamma-2" /><meta name="citation_keywords" content="COL17A1" /><meta name="citation_keywords" content="ITGB4" /><meta name="citation_keywords" content="LAMA3" /><meta name="citation_keywords" content="LAMB3" /><meta name="citation_keywords" content="LAMC2" /><meta name="citation_keywords" content="Junctional Epidermolysis Bullosa" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Junctional Epidermolysis Bullosa" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Ellen G Pfendner" /><meta name="DC.Contributor" content="Anne W Lucky" /><meta name="DC.Date" content="2018/12/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1125/" /><meta name="description" content="Junctional epidermolysis bullosa (JEB) is characterized by fragility of the skin and mucous membranes, manifest by blistering with little or no trauma. Blistering may be severe and granulation tissue can form on the skin around the oral and nasal cavities, fingers and toes, and internally around the upper airway. Blisters generally heal with no significant scarring. Broad classification of JEB includes JEB generalized severe and JEB generalized intermediate. In JEB generalized severe, blisters are present at birth or become apparent in the neonatal period. Congenital malformations of the urinary tract and bladder may also occur. In JEB generalized intermediate, the phenotype may be mild with blistering localized to hands, feet, knees, and elbows with or without renal or ureteral involvement. Some individuals never blister after the newborn period. Additional features shared by JEB and the other major forms of epidermolysis bullosa (EB) include congenital localized absence of skin (aplasia cutis congenita), milia, nail dystrophy, scarring alopecia, hypotrichosis, pseudosyndactyly, and other contractures." /><meta name="og:title" content="Junctional Epidermolysis Bullosa" /><meta name="og:type" content="book" /><meta name="og:description" content="Junctional epidermolysis bullosa (JEB) is characterized by fragility of the skin and mucous membranes, manifest by blistering with little or no trauma. Blistering may be severe and granulation tissue can form on the skin around the oral and nasal cavities, fingers and toes, and internally around the upper airway. Blisters generally heal with no significant scarring. Broad classification of JEB includes JEB generalized severe and JEB generalized intermediate. In JEB generalized severe, blisters are present at birth or become apparent in the neonatal period. Congenital malformations of the urinary tract and bladder may also occur. In JEB generalized intermediate, the phenotype may be mild with blistering localized to hands, feet, knees, and elbows with or without renal or ureteral involvement. Some individuals never blister after the newborn period. Additional features shared by JEB and the other major forms of epidermolysis bullosa (EB) include congenital localized absence of skin (aplasia cutis congenita), milia, nail dystrophy, scarring alopecia, hypotrichosis, pseudosyndactyly, and other contractures." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1125/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ebj/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1125/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CAD20E040C2110000000004F201E6.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1125_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1125_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/joubert/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/jh/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1125_"><span class="title" itemprop="name">Junctional Epidermolysis Bullosa</span></h1><p class="contrib-group"><span itemprop="author">Ellen G Pfendner</span>, PhD and <span itemprop="author">Anne W Lucky</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1125_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1125_ai__"><div class="contrib half_rhythm"><span itemprop="author">Ellen G Pfendner</span>, PhD<div class="affiliation small">Director, EBDx Program<br />GeneDx, Inc<br />Gaithersburg, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.xdeneg@nelle" class="oemail">moc.xdeneg@nelle</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Anne W Lucky</span>, MD<div class="affiliation small">Director, Cincinnati Children's Epidermolysis Bullosa Center<br />Cincinnati Children's Hospital<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@ykcul.enna" class="oemail">gro.cmhcc@ykcul.enna</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 22, 2008</span>; Last Update: <span itemprop="dateModified">December 20, 2018</span>.</p><p><em>Estimated reading time: 41 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ebj.Summary" itemprop="description"><h2 id="_ebj_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Junctional epidermolysis bullosa (JEB) is characterized by fragility of the skin and mucous membranes, manifest by blistering with little or no trauma. Blistering may be severe and granulation tissue can form on the skin around the oral and nasal cavities, fingers and toes, and internally around the upper airway. Blisters generally heal with no significant scarring. Broad classification of JEB includes JEB generalized severe and JEB generalized intermediate. In JEB generalized severe, blisters are present at birth or become apparent in the neonatal period. Congenital malformations of the urinary tract and bladder may also occur. In JEB generalized intermediate, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be mild with blistering localized to hands, feet, knees, and elbows with or without renal or ureteral involvement. Some individuals never blister after the newborn period. Additional features shared by JEB and the other major forms of epidermolysis bullosa (EB) include <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> localized absence of skin (aplasia cutis congenita), milia, nail dystrophy, scarring alopecia, hypotrichosis, pseudosyndactyly, and other contractures.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of JEB is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with characteristic clinical findings by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> that identifies <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in one of the genes associated with JEB: <i>COL17A1</i>, <i>ITGB4</i>, <i>LAMA3</i>, <i>LAMB3</i>, or <i>LAMC2</i>. Skin biopsy using transmission electron microscopy (TEM) and/or immunofluorescent antibody/antigen mapping can be performed but is no longer the preferred method of diagnosis.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Lance and drain new blisters and dress with three layers (primary: non-adherent; secondary: for stability and protection; third: elastic properties to ensure integrity); protect skin from shearing forces; teach caretakers proper handling of infants and children; treatment of granulation tissue with high-potency topical steroids, silver nitrate, electrocautery, or autologous skin grafts; antibiotics and antiseptics as needed for wound care and infection; dilation of esophageal strictures (rare); tracheostomy if appropriate; gastrostomy tube if needed; standard treatment of gastroesophageal disease; appropriate footwear and physical therapy to promote/preserve ambulation; psychosocial support, including social services and psychological counseling; appropriate management of chronic pain; regular dental care; treatment of urologic and renal disease using standard treatments.</p><p><i>Prevention of secondary complications:</i> Attention to fluid and electrolyte balance in severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants (especially sodium levels); nutritional support including feeding gastrostomy when necessary; calcium, vitamin D, zinc, and iron supplements.</p><p><i>Surveillance:</i> Annual screening for iron-deficiency anemia, zinc deficiency, vitamin D deficiency; periodic bone mineral density scanning for osteopenia and/or osteoporosis; periodic echocardiograms to evaluate for dilated cardiomyopathy; in the second decade of life, surveillance for squamous cell carcinoma is appropriate.</p><p><i>Agents/circumstances to avoid:</i> Ordinary medical tape or Band-Aids<sup>&#x000ae;</sup>, poorly fitting or coarse-textured clothing and footwear, activities that can traumatize the skin (e.g., hiking, mountain biking, contact sports).</p><p><i>Pregnancy management:</i> Consider cesarean section delivery to reduce trauma to the skin of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> fetus.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>JEB is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are usually obligate heterozygotes (i.e., carriers). Because <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> and uniparental isodisomy have been reported, <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status of parents needs to be confirmed with <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. At conception, each sib of an affected individual whose parents are both carriers has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. The offspring of an individual with autosomal recessive JEB are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Carrier testing for family members at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if both pathogenic variants have been identified in the family.</p></div></div><div id="ebj.Diagnosis"><h2 id="_ebj_Diagnosis_">Diagnosis</h2><div id="ebj.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Junctional epidermolysis bullosa (JEB) <b>should be suspected</b> in individuals who have fragility of the skin with:</p><ul><li class="half_rhythm"><div>Blistering with little or no trauma. Blistering may be mild or severe; however, blisters generally heal with no significant scarring.</div></li><li class="half_rhythm"><div>Significant oral and mucous membrane involvement</div></li></ul><p>Note: Blistering may be severe and granulation tissue can form on the skin around the oral and nasal cavities, fingers and toes, and internally in and around the upper airway and the trachea (see <a class="figpopup" href="/books/NBK1125/figure/ebj.F1/?report=objectonly" target="object" rid-figpopup="figebjF1" rid-ob="figobebjF1">Figure 1</a>, <a class="figpopup" href="/books/NBK1125/figure/ebj.F2/?report=objectonly" target="object" rid-figpopup="figebjF2" rid-ob="figobebjF2">Figure 2</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figebjF1" co-legend-rid="figlgndebjF1"><a href="/books/NBK1125/figure/ebj.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figebjF1" rid-ob="figobebjF1"><img class="small-thumb" src="/books/NBK1125/bin/ebj-Image001.gif" src-large="/books/NBK1125/bin/ebj-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndebjF1"><h4 id="ebj.F1"><a href="/books/NBK1125/figure/ebj.F1/?report=objectonly" target="object" rid-ob="figobebjF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">JEB generalized severe a. Extensive widespread blistering and granulation tissue on ear</p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figebjF2" co-legend-rid="figlgndebjF2"><a href="/books/NBK1125/figure/ebj.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figebjF2" rid-ob="figobebjF2"><img class="small-thumb" src="/books/NBK1125/bin/ebj-Image002.gif" src-large="/books/NBK1125/bin/ebj-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndebjF2"><h4 id="ebj.F2"><a href="/books/NBK1125/figure/ebj.F2/?report=objectonly" target="object" rid-ob="figobebjF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">JEB generalized intermediate e. Minor nail dystrophy in an older child</p></div></div></div><div id="ebj.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of JEB <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with one or both of the following:</p><ul><li class="half_rhythm"><div>Identification by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in one of the genes listed in <a class="figpopup" href="/books/NBK1125/table/ebj.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figebjTmoleculargenetictestingusedin" rid-ob="figobebjTmoleculargenetictestingusedin">Table 1</a></div></li><li class="half_rhythm"><div>Skin biopsy using transmission electron microscopy (TEM) and/or immunofluorescent antibody/antigen mapping (see <a href="#ebj.Skin_Biopsy">Skin Biopsy</a>)</div></li></ul><p>Note: Genetic testing is the preferred diagnostic method. Skin biopsy for diagnostic purposes is no longer routinely performed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is not conclusive.</p><div id="ebj.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>, targeted <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of junctional epidermolysis bullosa is broad, individuals with the distinctive findings described in <a href="#ebj.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#ebj.Skin_Biopsy">Option 1</a>), whereas those with a phenotype indistinguishable from many other inherited disorders with fragile skin and blistering, or presenting in the neonatal period before significant sequelae such as exuberant granulomatous tissue has developed, are more likely to be diagnosed using genomic testing (see <a href="#ebj.Skin_Biopsy">Option 2</a>).</p><p><b>Option 1</b></p><p>When the phenotypic and laboratory findings suggest the diagnosis of junctional epidermolysis bullosa, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> or <b>targeted molecular testing</b> [<a class="bk_pop" href="#ebj.REF.lucky.2018.188">Lucky et al 2018</a>].</p><p>A junctional epidermolysis bullosa <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>COL17A1</i>, <i>ITGB4</i>, <i>LAMB3</i>, <i>LAMA3</i>, <i>LAMC2</i>, and other genes of interest (see <a href="#ebj.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1125/table/ebj.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figebjTmoleculargenetictestingusedin" rid-ob="figobebjTmoleculargenetictestingusedin">Table 1</a>).</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>Option 2</b></p><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by skin fragility and blistering, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p><b>Exome array</b> (when clinically available) may be considered if <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="ebj.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Junctional Epidermolysis Bullosa</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1125/table/ebj.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebj.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of JEB Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>3</sup> Detectable by Test Method</th></tr><tr><th headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL17A1</i></td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12%</td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;98%</td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ITGB4</i></td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%&#x000a0;<sup>7</sup></td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td></tr><tr><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LAMA3</i></td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;98%&#x000a0;<sup>8</sup></td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LAMB3</i></td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%</td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;98%</td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2%&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LAMC2</i></td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;98%</td><td headers="hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebj.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2%&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ebj.TF.1.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="ebj.TF.1.2"><p class="no_margin">See <a href="/books/NBK1125/#ebj.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>3. </dt><dd><div id="ebj.TF.1.3"><p class="no_margin">See <a href="#ebj.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="ebj.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="ebj.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="ebj.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#ebj.REF.pulkkinen.1997a.611">Pulkkinen et al [1997a]</a>, <a class="bk_pop" href="#ebj.REF.takizawa.2000b.307">Takizawa et al [2000b]</a>, <a class="bk_pop" href="#ebj.REF.fassihi.2005.71">Fassihi et al [2005]</a>, <a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al [2006]</a></p></div></dd><dt>7. </dt><dd><div id="ebj.TF.1.7"><p class="no_margin">Biallelic pathogenic variants in <i>ITGB4</i> are a rare cause of JEB [Author, personal communication].</p></div></dd><dt>8. </dt><dd><div id="ebj.TF.1.8"><p class="no_margin">Care must be taken to sequence the <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> region of the longest transcript of <i>LAMA3</i> (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_198129.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_198129<wbr style="display:inline-block"></wbr>​.2</a>) rather than one of the shorter transcript variants.</p></div></dd><dt>9. </dt><dd><div id="ebj.TF.1.9"><p class="no_margin"><a class="bk_pop" href="#ebj.REF.pulkkinen.1995.77">Pulkkinen et al [1995]</a>, <a class="bk_pop" href="#ebj.REF.cserhalmifriedman.1998.105">Cserhalmi-Friedman et al [1998]</a>, <a class="bk_pop" href="#ebj.REF.takizawa.2000b.307">Takizawa et al [2000b]</a>, <a class="bk_pop" href="#ebj.REF.huber.2002.185">Huber et al [2002]</a>, <a class="bk_pop" href="#ebj.REF.micheloni.2004.796">Micheloni et al [2004]</a>, <a class="bk_pop" href="#ebj.REF.posteraro.2004.639">Posteraro et al [2004]</a></p></div></dd></dl></div></div></div></div><div id="ebj.Skin_Biopsy"><h4>Skin Biopsy</h4><p>Examination of a skin biopsy by (1) transmission electron microscopy (TEM) and/or (2) immunofluorescent antibody/antigen mapping is sometimes performed to establish the diagnosis of JEB.</p><p>A punch biopsy that includes the full basement membrane zone is preferred. The biopsy should be taken from the leading edge of a fresh (&#x0003c;12 hours old) blister or from a mechanically induced blister and should include some normal adjacent skin. (Older blisters undergo change that may obscure the diagnostic morphology and can be misleading.)</p><p>Note:</p><ul><li class="half_rhythm"><div><b>For TEM</b></div><ul><li class="half_rhythm"><div>Specimens must be placed in fixation medium (e.g., gluteraldehyde) as designated by the laboratory performing the test.</div></li><li class="half_rhythm"><div>Formaldehyde-fixed samples cannot be used for electron microscopy.</div></li></ul></li><li class="half_rhythm"><div><b>For immunofluorescent antibody/antigen mapping</b></div><ul><li class="half_rhythm"><div>Specimens should be sent in sterile carrying medium (e.g., Michel's or Zeus's) as specified by the laboratory performing the test.</div></li><li class="half_rhythm"><div>Some laboratories prefer flash-frozen tissue.</div></li><li class="half_rhythm"><div>In some laboratories the mapping only designates the level of the cleavage by using various marker antibodies of different layers of the basement membrane. A laboratory that has antigens for the proteins of interest in EB is preferred because both the level of cleavage and the presence or absence of the specific <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> products mutated in EB can be assessed.</div></li></ul></li><li class="half_rhythm"><div><b>Light microscopy</b> is inadequate and unacceptable for the accurate diagnosis of any subtypes of EB.</div></li></ul><p><b>Transmission electron microscopy (TEM)</b> is used to examine the number and morphology of basement membrane zone structures &#x02013; in particular: the number and morphology of anchoring fibrils; the presence of and morphology of hemidesmosomes, anchoring filaments, and keratin intermediate filaments; and the presence of microvesicles showing the tissue cleavage plane.</p><p>Findings on TEM in JEB include the following [<a class="bk_pop" href="#ebj.REF.shinkuma.2011.412">Shinkuma et al 2011</a>]:</p><ul><li class="half_rhythm"><div><b>All forms of JEB.</b> Splitting is seen in the lamina lucida of the basement membrane of the epidermis or just above the basement membrane at the level of the hemidesmosomes in the lowest level of the keratinocytes layer.</div></li><li class="half_rhythm"><div><b>JEB generalized severe.</b> Hemidesmosomes are hypoplastic and reduced in number. Anchoring filaments are markedly reduced or absent.</div></li><li class="half_rhythm"><div><b>JEB generalized intermediate.</b> Anchoring filaments may be reduced; hemidesmosomes may be reduced or hypoplastic.</div></li></ul><p><b>Immunofluorescent antibody/antigen mapping.</b> Findings include the following:</p><ul><li class="half_rhythm"><div>Abnormal or absent staining with antibodies to laminin 332 (aka LAM5) [<a class="bk_pop" href="#ebj.REF.aumailley.2005.326">Aumailley et al 2005</a>] resulting from pathogenic variants in <i>LAMA3</i>, <i>LAMB3</i>, or <i>LAMC2</i> in JEB generalized severe or JEB generalized intermediate</div></li><li class="half_rhythm"><div>Abnormal or absent staining with antibodies to collagen XVII in JEB caused by pathogenic variants in <i>COL17A1</i></div></li></ul><p>Normal staining for other antigens (e.g., collagen VII, keratins 5 and 14) confirms the diagnosis of JEB.</p><p>Note: Especially in milder forms of EB, indirect immunofluorescent studies are often not sufficient to make the diagnosis because near-normal antigen levels are detected and no cleavage plane is observed. In these cases electron microscopic examination of the skin biopsy must be performed.</p></div></div></div><div id="ebj.Clinical_Characteristics"><h2 id="_ebj_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ebj.Clinical_Description"><h3>Clinical Description</h3><p>Junctional epidermolysis bullosa (JEB) is characterized by fragility of the skin and mucous membranes, manifest by blistering with little or no trauma. Broad classification of JEB includes JEB generalized severe and JEB generalized intermediate and is based on severity and survival past the first years of life [<a class="bk_pop" href="#ebj.REF.yuen.2013.93">Yuen et al 2013</a>, <a class="bk_pop" href="#ebj.REF.kellymancuso.2014.159">Kelly-Mancuso et al 2014</a>].</p><p><b>JEB generalized severe</b> (previously called JEB Herlitz). Severe blistering is present at birth or becomes apparent in the neonatal period and may lead to large regions of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> skin with significant granulation tissue. Granulation tissue characteristically appears around the nose, mouth, ears, and tips of the fingers and toes as well as in areas subject to friction such as the buttocks and the back of the head. Persistent plaques on the face can be challenging to treat. The granulation tissue manifests as large eroded patches and plaques often with serpiginous or annular borders that are friable and bleed easily and profusely. There can be extensive loss of blood, fluid, and protein. Such erosions are often life threatening because they make these infants susceptible to electrolyte imbalance and infection including sepsis and sudden death. If the infant survives, blistering may continue throughout life, generally without scarring unless there has been severe secondary infection. Scarring pseudosyndactyly of the hands and feet fusing the digits into "mitten" hands and feet with severe loss of function has been seen in some of the individuals with JEB generalized severe who survive [<a class="bk_pop" href="#ebj.REF.fine.1999">Fine et al 1999</a>]. In one series, 73% of 71 children born in a five-year period died at an average age of five months [<a class="bk_pop" href="#ebj.REF.kellymancuso.2014.159">Kelly-Mancuso et al 2014</a>].</p><p>In addition to cutaneous involvement, mucosal involvement of the mouth, upper respiratory tract, esophagus, bladder, urethra, and corneas can be seen. Amelogenesis imperfecta with pitting of tooth enamel is common. Accumulation of granulation tissue surrounding the airway is usually subglottic and the first manifestation is a weak, hoarse cry. Eventually, compression and obstruction of the airway result in stridor and respiratory distress. Unless tracheostomy is performed, many children succumb from respiratory complications. However, managing a tracheostomy in a child with such fragile skin is difficult [<a class="bk_pop" href="#ebj.REF.ida.2012.657">Ida et al 2012</a>].</p><p>Bladder and urethral epithelial involvement can cause dysuria, urinary retention, urinary tract infections, and eventual renal compromise. Renal and ureteral anomalies that can be seen include dysplastic/multicystic kidney, hydronephrosis/hydroureter, acute renal tubular necrosis, obstructive uropathy, ureterocele, duplicated renal collecting system, and absent bladder [<a class="bk_pop" href="#ebj.REF.puvabanditsin.1997.359">Puvabanditsin et al 1997</a>, <a class="bk_pop" href="#ebj.REF.kambham.2000.190">Kambham et al 2000</a>, <a class="bk_pop" href="#ebj.REF.nakano.2000.493">Nakano et al 2000</a>, <a class="bk_pop" href="#ebj.REF.wallerstein.2000.286">Wallerstein et al 2000</a>, <a class="bk_pop" href="#ebj.REF.fine.2004.651">Fine et al 2004</a>, <a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>, <a class="bk_pop" href="#ebj.REF.pfendner.2007.781">Pfendner et al 2007</a>].</p><p>Esophageal narrowing has been reported, but is less common than in children with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> dystrophic EB.</p><p>Secondary complications common in JEB generalized severe include malnutrition and growth retardation, anemia, alopecia, cutaneous infection, sepsis, electrolyte imbalance, osteoporosis [<a class="bk_pop" href="#ebj.REF.fewtrell.2006.959">Fewtrell et al 2006</a>], dilated cardiomyopathy, squamous cell carcinoma [<a class="bk_pop" href="#ebj.REF.yuen.2011.780">Yuen &#x00026; Jonkman 2011</a>], and dental enamel dysplasia with pitting [<a class="bk_pop" href="#ebj.REF.kr_mer.2010.303">Kr&#x000e4;mer 2010</a>, <a class="bk_pop" href="#ebj.REF.stellingsma.2011.405">Stellingsma et al 2011</a>].</p><p>Most children with JEB generalized severe do not survive past the first year of life.</p><p><b>JEB generalized intermediate</b> (previously called JEB non-Herlitz) includes a spectrum of less severe clinical phenotypes than JEB generalized severe. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be mild with blistering localized to hands, feet, knees, and elbows with or without renal, ureteral, or esophageal involvement; or relatively more widespread including flexural areas and trunk. Some children virtually never blister after the newborn period. The severe granulation tissue and respiratory compromise seen in individuals with JEB generalized severe are rare.</p><p>Varying degrees of alopecia and onychodystrophy as well as dental enamel pitting remain hallmarks of this type of JEB.</p><p><b>Additional manifestations</b> of JEB generalized severe and JEB generalized intermediate include:</p><ul><li class="half_rhythm"><div>Congenital localized absence of skin (aplasia cutis congenita)</div></li><li class="half_rhythm"><div>Exuberant granulation tissue</div></li><li class="half_rhythm"><div>Nail dystrophy</div></li><li class="half_rhythm"><div>Scarring alopecia</div></li><li class="half_rhythm"><div>Squamous cell carcinoma in individuals with JEB generalized intermediate [<a class="bk_pop" href="#ebj.REF.montaudi_.2016.117">Montaudi&#x000e9; et al 2016</a>]</div></li><li class="half_rhythm"><div>Pseudosyndactyly and other contractures. Pseudosyndactyly is defined as the partial or complete loss of web spaces between any digits of the hands or feet (rare).</div></li><li class="half_rhythm"><div>Milia (rare)</div></li><li class="half_rhythm"><div>Scarring (rare)</div></li></ul></div><div id="ebj.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b>JEB generalized severe</b> is the result of <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> pathogenic variants on both alleles, which result in little or no functional protein [<a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>]. For frameshift variants, the severity may be related to where the stop codon is located and whether any functional (although truncated) protein is formed; the presence of some functional protein appears to be the most important factor in mitigating disease severity [<a class="bk_pop" href="#ebj.REF.kiritsi.2013.135">Kiritsi et al 2013</a>].</p><p>JEB generalized intermediate generally results from amino acid substitutions and splice-junction variants, although it is difficult to generalize because of the wide phenotypic variability and range of allelic variants that have been identified [<a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>]. In addition, moderation of phenotypes expected to be severe has occurred through <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> skipping of exons containing <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> or frameshift variants [<a class="bk_pop" href="#ebj.REF.mcgrath.1999.314">McGrath et al 1999</a>, <a class="bk_pop" href="#ebj.REF.kowalewski.2016.1375">Kowalewski et al 2016</a>].</p></div><div id="ebj.Nomenclature"><h3>Nomenclature</h3><div id="ebj.T.junctional_epidermolysis_bullosa_n" class="table"><h3><span class="label">Table 2: </span></h3><div class="caption"><p>Junctional Epidermolysis Bullosa Nomenclature</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1125/table/ebj.T.junctional_epidermolysis_bullosa_n/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebj.T.junctional_epidermolysis_bullosa_n_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Current Nomenclature</th><th id="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" style="text-align:left;vertical-align:middle;">2008 Nomenclature</th><th id="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" style="text-align:left;vertical-align:middle;">2013 "Onion Skin"<br />Nomenclature</th><th id="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" rowspan="2" scope="col" colspan="1" headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" style="text-align:left;vertical-align:top;">Other Specific JEB Designations<br />Used in the Past</th></tr><tr><th headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1" id="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">JEB Subtype</th><th headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1" id="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abbreviation</th></tr></thead><tbody><tr><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Generalized</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB, generalized severe</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB-gen sev</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Herlitz JEB<br />(H-JEB)</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB generalized severe, laminin-332 absent, <i>LAMA3</i>, <i>LAMB3</i>, or <i>LAMC2</i> pathogenic variants (specify type)</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Epidermolysis bullosa letalis</div></li><li class="half_rhythm"><div>Epidermolysis bullosa junctional Herlitz-Pearson</div></li><li class="half_rhythm"><div>Junctional epidermolysis bullosa mitis</div></li></ul>
</td></tr><tr><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">JEB, generalized intermediate</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB-gen intermed</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Non-Herlitz JEB<br />(NH-JEB)</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB generalized intermediate, laminin-332 or collagen XVII reduced staining, <i>LAMA3</i>, <i>LAMB3</i>, <i>LAMC2</i>, or <i>COL17A1</i> pathogenic (specify type)</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Epidermolysis bullosa, generalized atrophic benign (GABEB)</div></li><li class="half_rhythm"><div>Epidermolysis bullosa junctionalis, disentis type</div></li><li class="half_rhythm"><div>Epidermolysis bullosa junctionalis, progressive</div></li><li class="half_rhythm"><div>Epidermolysis bullosa junctionalis, severe non-lethal</div></li></ul>
</td></tr><tr><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">JEB with pyloric atresia</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB-PA</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">JEB-late onset</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB-LO</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">JEB with respiratory and renal involvement</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB-RR</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Localized</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB, localized</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB-loc</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">JEB, inversa</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JEB-inv; JEB-I</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">JEB-LOC syndrome</td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_1 hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ebj.T.junctional_epidermolysis_bullosa_n_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#ebj.REF.fine.2014.1103">Fine et al [2014]</a></p></div></dd><dt></dt><dd><div><p class="no_margin">JEB = junctional epidermolysis bullosa</p></div></dd></dl></div></div></div></div><div id="ebj.Prevalence"><h3>Prevalence</h3><p>According to the National EB Registry, prevalence of all types of JEB is 0.44 per million in the US population [<a class="bk_pop" href="#ebj.REF.fine.1999">Fine et al 1999</a>]. Recent data estimate the incidence of JEB at between 3.59 and 6.7 per million per year with a 73% mortality rate [<a class="bk_pop" href="#ebj.REF.kellymancuso.2014.159">Kelly-Mancuso et al 2014</a>, <a class="bk_pop" href="#ebj.REF.hammersen.2016.2150">Hammersen et al 2016</a>].</p><ul><li class="half_rhythm"><div>The prevalence of JEB generalized severe is estimated at 0.4 per million but may be underrepresented. JEB generalized severe incidence is also very low (0.41 per million), but is probably underestimated: many individuals with JEB generalized severe go unreported because infants succumb to the disease in the neonatal period (a mortality rate of 73% in infancy has been reported) [<a class="bk_pop" href="#ebj.REF.kellymancuso.2014.159">Kelly-Mancuso et al 2014</a>].</div></li><li class="half_rhythm"><div>JEB generalized intermediate incidence is 2.0 per million.</div></li><li class="half_rhythm"><div>Carrier risk of all forms of JEB in the US population has been calculated as 1:270 [Author, personal communication].</div></li><li class="half_rhythm"><div>Carrier risk of JEB generalized severe has been calculated as 1:781 [<a class="bk_pop" href="#ebj.REF.nakano.2000.493">Nakano et al 2000</a>, <a class="bk_pop" href="#ebj.REF.pfendner.2001.483">Pfendner et al 2001</a>].</div></li></ul></div></div><div id="ebj.Genetically_Related_Allelic_Disorder"><h2 id="_ebj_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>Allelic disorders with phenotypic characteristics similar to JEB generalized intermediate:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b><i>LAMA3</i>.</b> A related disorder, laryngoonychocutaneous syndrome (LOCS or Shabbir syndrome; OMIM <a href="http://omim.org/entry/245660" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">245660</a>), is described in Punjabi Indians and individuals of Iranian descent. LOCS has many phenotypic characteristics similar to JEB generalized severe. Skin fragility manifests as mild blistering and erosions of the hands and face that spread to other parts of the body and heal with crusted lesions. Neonates may have a hoarse cry and later laryngeal abnormalities and growths, conjunctival disease, abnormal nails, and hypoplastic dental enamel. Eventually, conjunctival disease may cause blindness and laryngeal disease may cause life-threatening airway obstruction requiring tracheostomy [<a class="bk_pop" href="#ebj.REF.cohn.2010.89">Cohn &#x00026; Murrell 2010</a>]. Two <i>LAMA3</i> pathogenic variants, c.151dupG and Gln57Ter in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 39 on one of three <i>LAMA3</i> <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>, have been identified as causative [<a class="bk_pop" href="#ebj.REF.mclean.2003.2395">McLean et al 2003</a>, <a class="bk_pop" href="#ebj.REF.barzegar.2013.1353">Barzegar et al 2013</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div><div class="half_rhythm">Diagnosis of LOCS may be complicated by the lack of a definitive cleavage plane on TEM and reduced but not absent laminin 5 staining by immunofluorescence for the basement membrane proteins. Sequence analysis of all 76 exons of <i>LAMA3</i>, which encodes all three <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>, is necessary to provide a definitive diagnosis, especially in neonates.</div></li><li class="half_rhythm"><div class="half_rhythm"><b><i>ITGB4</i>.</b> Biallelic pathogenic variants in <i>ITGB4</i> are more commonly associated with epidermolysis bullosa with pyloric atresia (EB-PA). More than 100 pathogenic variants spanning all of <i>ITGB4</i> have been described in EB-PA. Pathogenic variants that cause premature termination codons on both alleles result in the most severe phenotypes, which are frequently lethal in the neonatal period. EB-PA is characterized by fragility of the skin and mucous membranes, manifested by blistering with little or no trauma; <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> pyloric atresia; and ureteral and renal anomalies (dysplastic/multicystic kidney, hydronephrosis/hydroureter, ureterocele, duplicated renal collecting system, absent bladder). Biallelic pathogenic variants in <i>ITGB4</i> rarely cause <a href="/books/n/gene/ebs/"><b>epidermolysis</b> bullosa simplex</a> (EBS) or pyloric atresia with desquamative enteropathy and no skin disease [<a class="bk_pop" href="#ebj.REF.salvestrini.2008.585">Salvestrini et al 2008</a>].</div></li></ul><p>Other allelic disorders (not in the differential diagnosis of JEB):</p><ul><li class="half_rhythm"><div><b><i>COL17A1</i>.</b> Pathogenic variants in <i>COL17A1</i> may also be associated with an epidermal keratinocyte cleavage plane usually associated with <a href="/books/n/gene/ebs/">epidermolysis bullosa simplex</a>.</div></li><li class="half_rhythm"><div><b><i>LAMB3</i> and <i>LAMA3</i></b> pathogenic variants are associated with hypoplastic amelogenesis imperfecta [<a class="bk_pop" href="#ebj.REF.yuen.2012.695">Yuen et al 2012</a>, <a class="bk_pop" href="#ebj.REF.kim.2013.899">Kim et al 2013</a>, <a class="bk_pop" href="#ebj.REF.poulter.2014.132">Poulter et al 2014</a>, <a class="bk_pop" href="#ebj.REF.lee.2015.90">Lee et al 2015</a>, <a class="bk_pop" href="#ebj.REF.wang.2015.e0116514">Wang et al 2015</a>, <a class="bk_pop" href="#ebj.REF.gosty_ska.2016.94">Gosty&#x00144;ska et al 2016</a>, <a class="bk_pop" href="#ebj.REF.du.2018.689">Du et al 2018</a>].</div></li></ul><p><b><i>LAMC2.</i></b> No phenotypes other than JEB are known to be associated with pathogenic variants in <i>LAMC2</i>.</p></div><div id="ebj.Differential_Diagnosis"><h2 id="_ebj_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Epidermolysis bullosa (EB).</b> According to the 2014 classification system, the four major types of EB, caused by pathogenic variants in 18 different genes, are EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome (KS) [<a class="bk_pop" href="#ebj.REF.fine.2014.1103">Fine et al 2014</a>]. Classification into major type is based on the location of blistering in relation to the dermal-epidermal junction of skin. Subtypes are predominantly determined by clinical features and supported by molecular diagnosis.</p><p>The four major types of EB share easy fragility of the skin (and mucosa in many cases), manifested by blistering with little or no trauma. Although clinical examination is useful in determining the extent of blistering and the presence of oral and other mucous membrane lesions, defining characteristics such as the presence and extent of scarring &#x02013; especially in young children and neonates &#x02012; may not be established or significant enough to allow identification of EB type; thus, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (or less commonly skin biopsy) is usually required to establish the most precise diagnosis. The ability to induce blisters with friction (although the amount of friction can vary) and to enlarge blisters by applying pressure to the blister edge is common to all; mucosal and nail involvement and the presence or absence of milia may not be helpful discriminators.</p><p>Post-inflammatory changes, such as those seen in generalized severe EBS (EBS-gen sev), are often mistaken for scarring or mottled pigmentation. Scarring can occur in EBS and JEB as a result of infection of erosions or scratching, which further damage the exposed surface. Congenital absence of the skin can be seen in any of the four major types of EB and is not a discriminating diagnostic feature.</p><p>Corneal erosions, esophageal strictures, and nail involvement may indicate either DEB or JEB. In milder presentations, scarring (especially of the dorsal hands and feet) suggests DEB. Pseudosyndactyly (mitten deformities) resulting from scarring of the hands and feet in older children and adults usually suggests DEB.</p><p><a href="/books/n/gene/ebs/"><b>Epidermolysis bullosa simplex</b></a>
<b>(EBS)</b> is characterized by fragility of the skin that results in nonscarring blisters caused by little or no trauma. The four most common clinical subtypes of EBS range from relatively mild blistering of the hands and feet to more generalized blistering, which can be fatal. The majority of individuals with EBS have <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (or rarely <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a>) pathogenic variants in <i>KRT5</i> or <i>KRT14</i>. More recently, variants in <i>EXPH5</i>, <i>TGM5</i>, <i>DST</i>, <i>ITGA3</i>, <i>KLHL24</i>, and <i>CD151</i> have been described.</p><ul><li class="half_rhythm"><div>In <b>EBS, localized</b> (EBS-loc; previously known as Weber-Cockayne type), blisters are rarely present at birth and may occur on the knees and shins with crawling or on the feet at approximately age 18 months; some individuals manifest the disease in adolescence or early adulthood. Blisters are usually confined to the hands and feet, but can occur anywhere if trauma is significant.</div></li><li class="half_rhythm"><div>In <b>EBS, generalized intermediate</b> (<b>EBS-gen intermed</b>; previously known as Koebner type), blisters may be present at birth or develop within the first few months of life. Involvement is more widespread than in EBS-loc, but generally milder than in EBS-gen sev.</div></li><li class="half_rhythm"><div>In <b>EBS with mottled pigmentation type (EBS-MP)</b>, skin fragility is evident at birth and clinically indistinguishable from EBS-gen sev; over time, progressive brown pigmentation interspersed with depigmented spots develops on the trunk and extremities, the pigmentation disappearing in adult life. Focal palmar and plantar hyperkeratoses may occur.</div></li><li class="half_rhythm"><div>In <b>EBS, generalized severe</b> (<b>EBS-gen sev</b>; previously known as Dowling-Meara type), onset is usually at birth; severity varies greatly, both within and among families. Widespread and severe blistering and/or multiple grouped clumps of small blisters are typical and hemorrhagic blisters are common. Improvement occurs during mid- to late childhood. Progressive hyperkeratosis of the palms and soles begins in childhood and may be the major complaint of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in adult life. Nail dystrophy and milia are common. Both hyperpigmentation and hypopigmentation can occur. Mucosal involvement in EBS-gen sev may interfere with feeding. Blistering can be severe enough to result in neonatal or infant death.</div></li></ul><p><b>EB caused by pathogenic variants in <i>PLEC</i></b> (OMIM <a href="http://omim.org/entry/601282" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601282</a>) can vary from relatively mild, previously known as the Ogna form, to more severe and sometimes lethal. Up to 8% of EBS may be caused by <i>PLEC</i> pathogenic variants. In most individuals with <i>PLEC</i> pathogenic variants, the associated phenotypes (i.e., EB with muscular dystrophy [EB-MD], EB with pyloric atresia [EB-PA]) are more complex:</p><ul><li class="half_rhythm"><div><b>EB-MD</b> (OMIM <a href="http://omim.org/entry/226670" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">226670</a>). More than 50 individuals with EB-MD have been reported worldwide. Blistering occurs early and is generally mild. Muscular dystrophy may not appear until later childhood, adolescence, or adulthood, and can cause immobility and eventually death later in life. Pathogenic variants have been described throughout <i>PLEC</i> but seem to cluster in the two long open reading frames containing exons in the 3' end of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. Nonsense, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a>/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, and splice-junction variants have been described. The mildest phenotypes are usually associated with <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> insertions or deletions, which do not alter the reading frame of the microRNA (<a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>). Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/eb-pa/"><b>EB-PA</b></a><b>.</b> In several US and Japanese families, EB-PA is associated with premature termination variants in <i>PLEC</i>. EB-PA is more commonly associated with <i>ITGB4</i> pathogenic variants, and rarely <i>ITGA6</i> pathogenic variants. Although disease course is severe and often lethal in the neonatal period, non-lethal forms have been described. Individuals with pathogenic variants in <i>ITGB4</i> or <i>ITGA6</i> may also have renal and ureteral anomalies, including dysplastic/multicystic kidney, hydronephrosis/hydroureter, acute renal tubular necrosis, obstructive uropathy, ureterocele, duplicated renal collecting system, and absent bladder. Occasionally, pyloric atresia may be suspected during gestation as a result of oligohydramnios, with or without elevated alpha-fetoprotein and acetylcholinesterase levels, and echogenic material in the amniotic fluid.</div></li></ul><p><a href="/books/n/gene/ebd/"><b>Dystrophic EB</b></a>
<b>(DEB).</b> The blister forms below the basement membrane, in the superficial dermis. The basement membrane is attached to the blister roof, resulting in scarring when blisters heal. Pathogenic variants in <i>COL7A1</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding type VII collagen, have been demonstrated in all forms of DEB, both dominant and recessive.</p></div><div id="ebj.Management"><h2 id="_ebj_Management_">Management</h2><div id="ebj.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with junctional epidermolysis bullosa (JEB), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Evaluation of the sites of blister formation, including mouth, esophagus, and airway in a child with progressive hoarseness or stridor</div></li><li class="half_rhythm"><div>Direct examination of the airway by an experienced otolaryngologist with appropriately small and lubricated instruments to determine the extent of airway compromise so that decisions regarding tracheostomy can be discussed with the family</div></li><li class="half_rhythm"><div>Evaluation for gastroesophageal reflux disease, which may cause additional trauma to the upper airway [<a class="bk_pop" href="#ebj.REF.ida.2012.657">Ida et al 2012</a>]</div></li><li class="half_rhythm"><div>Evaluation for existing osteopenia through skeletal radiographs or DEXA scan</div></li><li class="half_rhythm"><div>Evaluation for cardiomyopathy by clinical evaluation and/or echocardiogram [Fine et all 2008]</div></li><li class="half_rhythm"><div>Measurements of hemoglobin and electrolytes to evaluate for anemia and electrolyte imbalance</div></li><li class="half_rhythm"><div>Skin bacterial cultures and blood cultures in clinically ill infants to decide appropriate antibiotic treatment</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul><p>Note: Clinical decision making in children who manifest sign and symptoms of severe JEB with a very poor prognosis has been debated and remains difficult [<a class="bk_pop" href="#ebj.REF.hammersen.2016.2150">Hammersen et al 2016</a>].</p></div><div id="ebj.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Skin.</b> The skin needs to be protected from shearing forces and caretakers need to learn how to handle the child with EB [<a class="bk_pop" href="#ebj.REF.denyer.2010.257">Denyer 2010</a>, <a class="bk_pop" href="#ebj.REF.pope.2012.904">Pope et al 2012</a>].</p><p>New blisters should be lanced and drained to prevent further spread from fluid pressure. In most cases, dressings for blisters involve three layers:</p><ul><li class="half_rhythm"><div>A primary non-adherent dressing that does not strip the top layers of the epidermis. Tolerance to different primary layers varies. Primary layers include the following:</div><ul><li class="half_rhythm"><div>Ordinary Band-Aids<sup>&#x000ae;</sup></div></li><li class="half_rhythm"><div>Dressings impregnated with an emollient such as petrolatum or topical antiseptic (e.g., Vaseline<sup>&#x000ae;</sup> gauze, Adaptic<sup>&#x000ae;</sup>, Xeroform<sup>&#x000ae;</sup>)</div></li><li class="half_rhythm"><div>Nonstick products (e.g., Telfa<sup>&#x000ae;</sup>, N-terface<sup>&#x000ae;</sup>)</div></li><li class="half_rhythm"><div>Silicone-based products without adhesive (e.g., Mepitel<sup>&#x000ae;</sup>, Mepilex<sup>&#x000ae;</sup>)</div></li></ul></li><li class="half_rhythm"><div>A secondary layer that provides stability for the primary layer and adds padding to allow more activity. Rolls of gauze (e.g., Conform<sup>&#x000ae;</sup> , Flexicon<sup>&#x000ae;</sup>) are commonly used.</div></li><li class="half_rhythm"><div>A tertiary layer that usually has some elastic properties and ensures the integrity of the dressing (e.g., Coban<sup>&#x000ae;</sup> or elasticized tube gauze of varying diameters such as Band Net<sup>&#x000ae;</sup> or Tubifast<sup>&#x000ae;</sup>)</div></li></ul><p>Treatment of granulation tissue can be attempted with high-potency topical steroids, silver nitrate, electrocautery, or autologous skin grafts.</p><p><b>Other.</b> The most common secondary complication in individuals with JEB is infection. In addition to wound care, treatment of chronic infection of wounds is a challenge. Many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals become infected with resistant bacteria, most often methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and <i>Pseudomonas aeruginosa</i>. Both antibiotics and antiseptics need to be employed.</p><p>Esophageal strictures and webs can be dilated repeatedly to improve swallowing [<a class="bk_pop" href="#ebj.REF.azizkhan.2007.801">Azizkhan et al 2007</a>].</p><p>A hoarse cry in an infant should alert to the possibility of airway obstruction with granulation tissue or other upper airway abnormalities. Decisions about tracheostomy should involve the family and take into consideration the medical condition of the infant. Because of the poor prognosis and severe pain and discomfort experienced by these infants, discussions with the family and a hospital ethics committee often help to determine the type of intervention and comfort care to provide [<a class="bk_pop" href="#ebj.REF.yan.2007.307">Yan et al 2007</a>, <a class="bk_pop" href="#ebj.REF.ida.2012.657">Ida et al 2012</a>].</p><p>Gastroesophageal reflux disease, when present, should be treated as in the general population.</p><p>Some children have delays or difficulty walking because of blistering and hyperkeratosis. Appropriate footwear and physical therapy are essential to preserve ambulation.</p><p>Psychosocial support, including social services and psychological counseling, is essential [<a class="bk_pop" href="#ebj.REF.lucky.2007.809">Lucky et al 2007</a>].</p><p>Pain management becomes an important part of daily care [<a class="bk_pop" href="#ebj.REF.goldschneider.2014.178">Goldschneider et al 2014</a>]. In those with difficult-to-control pain, referral to a pain management specialist can be considered.</p><p>Dental care is necessary because of inherent enamel abnormalities [<a class="bk_pop" href="#ebj.REF.kirkham.2000.377">Kirkham et al 2000</a>, <a class="bk_pop" href="#ebj.REF.kr_mer.2012.1">Kr&#x000e4;mer et al 2012</a>].</p><p>Urologic and renal problems may be serious in this population [<a class="bk_pop" href="#ebj.REF.kajbafzadeh.2010.1763">Kajbafzadeh et al 2010</a>]. For those <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who survive, referral to a urologist may be considered.</p></div><div id="ebj.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>The following are indicated:</p><ul><li class="half_rhythm"><div>Management of fluid and electrolyte deficiencies in the neonatal period and in infants with widespread disease</div></li><li class="half_rhythm"><div>Nutritional support including a feeding gastrostomy tube for infants and children with inadequate caloric intake and failure to thrive</div></li><li class="half_rhythm"><div>Calcium and vitamin D replacement for osteopenia and osteoporosis</div></li><li class="half_rhythm"><div>Zinc supplementation for wound healing</div></li><li class="half_rhythm"><div>Treatment of iron-deficiency anemia with oral or intravenous iron infusions and red blood cell transfusions</div></li></ul></div><div id="ebj.Surveillance"><h3>Surveillance</h3><p>Surveillance includes the following:</p><ul><li class="half_rhythm"><div>Annual complete blood counts and measurement of serum iron concentration to screen for iron-deficiency anemia</div></li><li class="half_rhythm"><div>Annual measurement of serum zinc concentration to screen for zinc deficiency</div></li><li class="half_rhythm"><div>Annual measurement of serum vitamin D</div></li><li class="half_rhythm"><div>Screening with bone mineral density scanning may detect early osteopenia and/or osteoporosis. No guidelines have been established regarding the age at which this should be initiated.</div></li><li class="half_rhythm"><div>Screening for dilated cardiomyopathy with periodic echocardiograms [<a class="bk_pop" href="#ebj.REF.laracorrales.2010.238">Lara-Corrales et al 2010</a>]</div></li><li class="half_rhythm"><div>Skin examination starting in the second decade of life for wounds that do not heal, have exuberant scar tissue, or otherwise look abnormal to screen for squamous cell carcinoma. Frequent biopsies of suspicious lesions followed by local excision may be necessary.</div></li></ul></div><div id="ebj.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Most persons with JEB cannot use ordinary medical tape or Band-Aids<sup>&#x000ae;</sup>. Silicone-based products provide a good substitute for tape.</p><p>Poorly fitting or coarse-textured clothing and footwear can cause trauma.</p><p>Activities such as hiking, mountain biking, and contact sports traumatize the skin; <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who are determined to participate in such activities should be encouraged to find creative ways to protect their skin.</p></div><div id="ebj.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#ebj.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ebj.Pregnancy_Management"><h3>Pregnancy Management</h3><p><b>Cesarean section</b> may be recommended to reduce trauma to the skin of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> fetus during delivery.</p></div><div id="ebj.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Several approaches to <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> for JEB, focused on retroviral modification of in vitro epidermal cells, have been proposed [<a class="bk_pop" href="#ebj.REF.robbins.2001.5193">Robbins et al 2001</a>, <a class="bk_pop" href="#ebj.REF.ortizurda.2003.1099">Ortiz-Urda et al 2003</a>]. One successful clinical trial has been conducted using transplantation of sheets of genetically modified epidermal stem cells in one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>LAMB3</i> pathogenic variants [<a class="bk_pop" href="#ebj.REF.mavilio.2006.1397">Mavilio et al 2006</a>, <a class="bk_pop" href="#ebj.REF.di_nunzio.2008.1977">Di Nunzio et al 2008</a>, <a class="bk_pop" href="#ebj.REF.de_rosa.2013.1">De Rosa et al 2013</a>]. Animal models include intra-amniotic prenatal laminin 332 delivery in mouse [<a class="bk_pop" href="#ebj.REF.m_hle.2006.1665">M&#x000fc;hle et al 2006</a>, <a class="bk_pop" href="#ebj.REF.endo.2012.561">Endo et al 2012</a>] and a spontaneous form of JEB in dog [<a class="bk_pop" href="#ebj.REF.capt.2005.530">Capt et al 2005</a>, <a class="bk_pop" href="#ebj.REF.spirito.2006.769">Spirito et al 2006</a>].</p><p>The use of a variety of viral vectors, including AAV [<a class="bk_pop" href="#ebj.REF.melo.2014.725">Melo et al 2014</a>], lentivirus [<a class="bk_pop" href="#ebj.REF.endo.2012.561">Endo et al 2012</a>], and retroviruses [<a class="bk_pop" href="#ebj.REF.mavilio.2006.1397">Mavilio et al 2006</a>, <a class="bk_pop" href="#ebj.REF.de_rosa.2013.1">De Rosa et al 2013</a>], is being explored to correct the pathogenic variants in cells cultured from individuals with JEB in preparation for transplantation back onto severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sites, and shows promise for future clinical trials. In an expedited trial in a single individual, retroviral mediated correction of autologous skin keratinocytes transplanted back onto affected sites also led to stem cell correction and the formation of a self-renewing keratinocyte population and replacement of mutated keratinocytes, leading to whole-body correction of the JEB <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ebj.REF.hirsch.2017.327">Hirsch et al 2017</a>].</p><p>Natural <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> is being investigated using autologous revertant cells cultured from patches of non-blistering skin [<a class="bk_pop" href="#ebj.REF.gosty_ski.2014.98">Gosty&#x00144;ski et al 2014</a>], and the pluripotent stem cells that can be generated from these revertant cells [<a class="bk_pop" href="#ebj.REF.umegakiarao.2014.264ra164">Umegaki-Arao et al 2014</a>].</p><p>The knockout mouse model for all JEB-related genes should facilitate the development of these therapeutic approaches [<a class="bk_pop" href="#ebj.REF.jiang.2005.xi">Jiang &#x00026; Uitto 2005</a>, <a class="bk_pop" href="#ebj.REF.bubier.2010.1819">Bubier et al 2010</a>, <a class="bk_pop" href="#ebj.REF.hammersen.2015.921">Hammersen et al 2015</a>]. Large animal models, such as dog and horse, have also been described [<a class="bk_pop" href="#ebj.REF.nagata.1997.445">Nagata et al 1997</a>, <a class="bk_pop" href="#ebj.REF.spirito.2002.684">Spirito et al 2002</a>, <a class="bk_pop" href="#ebj.REF.capt.2005.530">Capt et al 2005</a>, <a class="bk_pop" href="#ebj.REF.spirito.2006.769">Spirito et al 2006</a>, <a class="bk_pop" href="#ebj.REF.pertica.2010.751">Pertica et al 2010</a>]. Animal models that have been used to study EB were reviewed in <a class="bk_pop" href="#ebj.REF.natsuga.2010.137">Natsuga et al [2010]</a>.</p><p>Induced pleuripotent stem cells (IPS) are being studied in several laboratories around the world to address the treatment of JEB and other types of EB [<a class="bk_pop" href="#ebj.REF.osborn.2013.1151">Osborn et al 2013</a>, <a class="bk_pop" href="#ebj.REF.tolar.2013.562">Tolar et al 2013</a>].</p><p>Protein replacement therapy with LAMB3 has been studied in vitro [<a class="bk_pop" href="#ebj.REF.igoucheva.2008.1476">Igoucheva et al 2008</a>] with promising results.</p><p>The use of gentamicin as a chemical agent to induce read-through of pathogenic premature termination codons in keratinocytes containing expression vectors with various <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants has also been explored and has shown promising results in cell cultures, but has not yet been demonstrated in individuals with JEB [<a class="bk_pop" href="#ebj.REF.lincoln.2018">Lincoln et al 2018</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="ebj.Genetic_Counseling"><h2 id="_ebj_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ebj.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Junctional epidermolysis bullosa (JEB) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p>While there is no evidence to date that a single (i.e., <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>COL17A1</i>, <i>LAMA3</i>, <i>LAMB3</i>, or <i>LAMC2</i> results in JEB, dental anomalies have been reported in individuals who have a heterozygous <i>LAMB3</i>, <i>LAMA3</i>, or <i>COL17A1</i> variant [<a class="bk_pop" href="#ebj.REF.mcgrath.1996.781">McGrath et al 1996</a>, <a class="bk_pop" href="#ebj.REF.almaani.2009.1094">Almaani et al 2009</a>, <a class="bk_pop" href="#ebj.REF.yuen.2012.695">Yuen et al 2012</a>, <a class="bk_pop" href="#ebj.REF.kim.2013.899">Kim et al 2013</a>, <a class="bk_pop" href="#ebj.REF.poulter.2014.132">Poulter et al 2014</a>, <a class="bk_pop" href="#ebj.REF.lee.2015.90">Lee et al 2015</a>, <a class="bk_pop" href="#ebj.REF.wang.2015.e0116514">Wang et al 2015</a>, <a class="bk_pop" href="#ebj.REF.gosty_ska.2016.94">Gosty&#x00144;ska et al 2016</a>, <a class="bk_pop" href="#ebj.REF.du.2018.689">Du et al 2018</a>].</p></div><div id="ebj.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are usually obligate heterozygotes (i.e., carriers of one <i>COL17A1</i>, <i>ITGB4</i>, <i>LAMA3</i>, <i>LAMB3</i>, or <i>LAMC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Because <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> and uniparental isodisomy have been reported [<a class="bk_pop" href="#ebj.REF.pulkkinen.1997a.611">Pulkkinen et al 1997a</a>, <a class="bk_pop" href="#ebj.REF.takizawa.2000b.307">Takizawa et al 2000b</a>, <a class="bk_pop" href="#ebj.REF.cserhalmifriedman.2002.468">Cserhalmi-Friedman et al 2002</a>, <a class="bk_pop" href="#ebj.REF.fassihi.2005.71">Fassihi et al 2005</a>], <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status of parents needs to be confirmed with <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic except in a few rare instances where carriers of a <i>COL17A1</i>, <i>LAMA3</i>, or <i>LAMB3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have been reported to have dental enamel hypoplasia and/or pitting with resulting caries [<a class="bk_pop" href="#ebj.REF.nakamura.2006.333">Nakamura et al 2006</a>, <a class="bk_pop" href="#ebj.REF.murrell.2007.1772">Murrell et al 2007</a>, <a class="bk_pop" href="#ebj.REF.yuen.2012.695">Yuen et al 2012</a>, <a class="bk_pop" href="#ebj.REF.kim.2013.899">Kim et al 2013</a>, <a class="bk_pop" href="#ebj.REF.poulter.2014.132">Poulter et al 2014</a>, <a class="bk_pop" href="#ebj.REF.lee.2015.90">Lee et al 2015</a>, <a class="bk_pop" href="#ebj.REF.wang.2015.e0116514">Wang et al 2015</a>, <a class="bk_pop" href="#ebj.REF.gosty_ska.2016.94">Gosty&#x00144;ska et al 2016</a>, <a class="bk_pop" href="#ebj.REF.du.2018.689">Du et al 2018</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual whose parents are both carriers has a 25% chance of being affected, a 50% chance of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic except in the case of <i>COL17A1</i> or <i>LAMB3</i> pathogenic variants, where carriers may exhibit dental enamel hypoplasia and/or pitting and caries [<a class="bk_pop" href="#ebj.REF.nakamura.2006.333">Nakamura et al 2006</a>, <a class="bk_pop" href="#ebj.REF.murrell.2007.1772">Murrell et al 2007</a>, <a class="bk_pop" href="#ebj.REF.kim.2013.899">Kim et al 2013</a>, <a class="bk_pop" href="#ebj.REF.poulter.2014.132">Poulter et al 2014</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> JEB are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> parents is at a 50% risk of being a carrier of a <i>COL17A1</i>, <i>ITGB4</i>, <i>LAMA3</i>, <i>LAMB3</i>, or <i>LAMC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="ebj.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p></div><div id="ebj.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ebj.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>COL17A1</i>, <i>ITGB4</i>, <i>LAMA3</i>, <i>LAMB3</i>, or <i>LAMC2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for JEB are possible.</p><p><b>Fetoscopy.</b> Electron microscopic evaluation of fetal skin biopsies obtained by fetoscopy is also diagnostic in JEB. Fetoscopy carries a greater risk to pregnancy than CVS or amniocentesis and is performed relatively late (18-20 weeks) in gestation. Prenatal diagnosis for JEB using fetoscopy is not currently available in the US, but may be available in Europe.</p></div></div><div id="ebj.Resources"><h2 id="_ebj_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>DEBRA International</b></div><div>Am Heumarkt 27/3</div><div>Vienna 1030</div><div>Austria</div><div><b>Phone:</b> +43 1 876 40 30-0</div><div><b>Fax:</b> +43 1 876 40 30-30</div><div><b>Email:</b> office@debra-international.org</div><div><a href="http://www.debra-international.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.debra-international.org</a></div></li><li class="half_rhythm"><div><b>DebRA of America, Inc. (Dystrophic Epidermolysis Bullosa Research Association)</b></div><div>16 East 41st Street</div><div>3rd Floor</div><div>New York NY 10017</div><div><b>Phone:</b> 866-332-7276 (toll-free); 212-868-1573</div><div><b>Email:</b> staff@debra.org</div><div><a href="http://www.debra.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.debra.org</a></div></li><li class="half_rhythm"><div><b>DebRA UK</b></div><div>DebRA House</div><div>13 Wellington Business Park</div><div>Crowthorne Berkshire RG45 6LS</div><div>United Kingdom</div><div><b>Phone:</b> +44 01344 771961</div><div><b>Fax:</b> +44 01344 762661 </div><div><b>Email:</b> debra@debra.org.uk</div><div><a href="http://www.debra.org.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.debra.org.uk</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Junctional%20Epidermolysis%20Bullosa&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Junctional Epidermolysis Bullosa</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/001457.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epidermolysis bullosa</a></div></li><li class="half_rhythm"><div><b>EBCare Registry</b></div><div><i>The EBCare Registry is a resource for individuals and families <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by all forms of epidermolysis bullosa (EB) and qualified researchers working on approved EB research projects.</i></div><div><b>Phone:</b> 866-332-7276</div><div><b>Fax:</b> 888-363-0790</div><div><b>Email:</b> coordinator@EBCare.org</div><div><a href="http://ebcare.patientcrossroads.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ebcare.patientcrossroads.org</a></div></li></ul></div><div id="ebj.Molecular_Genetics"><h2 id="_ebj_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ebj.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Junctional Epidermolysis Bullosa: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1125/table/ebj.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebj.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ebj.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ebj.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ebj.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ebj.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ebj.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ebj.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ebj.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1308" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>COL17A1</i></a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1308" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">10q25<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9UMD9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Collagen alpha-1(XVII) chain</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/COL17A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL17A1 @ LOVD</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL17A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL17A1</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=COL17A1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL17A1</a></td></tr><tr><td headers="hd_b_ebj.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3691" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ITGB4</i></a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3691" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q25<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P16144" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Integrin beta-4</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ITGB4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ITGB4 database</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ITGB4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ITGB4</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ITGB4[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ITGB4</a></td></tr><tr><td headers="hd_b_ebj.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3909" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>LAMA3</i></a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3909" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">18q11<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q16787" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Laminin subunit alpha-3</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/LAMA3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMA3 database</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LAMA3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMA3</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=LAMA3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMA3</a></td></tr><tr><td headers="hd_b_ebj.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3914" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>LAMB3</i></a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3914" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q32<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q13751" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Laminin subunit beta-3</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/LAMB3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMB3 database</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LAMB3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMB3</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=LAMB3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMB3</a></td></tr><tr><td headers="hd_b_ebj.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3918" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>LAMC2</i></a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3918" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q25<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q13753" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Laminin subunit gamma-2</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/LAMC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMC2 database</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LAMC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMC2</a></td><td headers="hd_b_ebj.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=LAMC2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMC2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ebj.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ebj.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Junctional Epidermolysis Bullosa (<a href="/omim/113811,147557,150292,150310,226650,226700,226730,600805" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1125/table/ebj.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebj.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/113811" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">113811</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLLAGEN, TYPE XVII, ALPHA-1; COL17A1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/147557" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">147557</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INTEGRIN, BETA-4; ITGB4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/150292" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">150292</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LAMININ, GAMMA-2; LAMC2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/150310" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">150310</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LAMININ, BETA-3; LAMB3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/226650" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">226650</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/226700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">226700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/226730" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">226730</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600805" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600805</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LAMININ, ALPHA-3; LAMA3</td></tr></tbody></table></div></div><div id="ebj.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>The proteins encoded by <i>LAMA3</i>, <i>LAMB3</i>, and <i>LAMC2</i> assemble into the laminin 332 heterotrimer (aka LAM5 [<a class="bk_pop" href="#ebj.REF.aumailley.2005.326">Aumailley et al 2005</a>]). A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in these genes can lead to reduced resistance to minor trauma and the resulting mucocutaneous blistering that is the hallmark of junctional epidermolysis bullosa (JEB) (reviewed by <a class="bk_pop" href="#ebj.REF.kiritsi.2013.135">Kiritsi et al [2013]</a>). The type of variant, the biochemical properties of the substituted amino acid, if present, and its location determine the severity of the blistering <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (see <a href="#ebj.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>). Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants predominate in the severe forms of JEB and result in the absence of one of the three proteins that assemble into laminin 332. Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in key positions of the protein subunits affect the ability of the laminin &#x003b1;3, &#x003b2;3, and &#x003b3;2 polypeptides to assemble into a trimeric molecule, its secondary structure, and its ability to form the intracellular anchoring fibrils of the lamina densa.</p><p>Collagen XVII forms an integral part of the hemidesmosome and has an intracellular as well as extracellular component. There is evidence that it interacts with alpha-6 integrin within the hemidesmosome. The hemidesmosomes &#x02013; structures made up of several protein components including COLXVII, alpha-6 beta-4 integrin, BPAG1, and plectin &#x02013; anchor the epidermal cells to the underlying dermis. The type and position of variants in <i>COL17A1</i> determine whether some partially functional protein is made and also affect the level of the cleavage plane of the skin. In some cases, variants affecting the intracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> result in a cleavage plane within the lowest level of the basal keratinocytes usually associated with epidermolysis bullosa simplex (EBS) [<a class="bk_pop" href="#ebj.REF.charlesworth.2003.1344">Charlesworth et al 2003</a>].</p><p>Integrins associate in pairs containing one alpha and one beta chain. &#x003b1;6&#x003b2;4 integrin comprises one &#x003b1;6 and one &#x003b2;4 integrin from the integrin family of proteins and is a component of the hemidesmosomes of the epidermis. Integrins are known to participate in cell adhesion as well as cell-surface-mediated signaling. Insertion/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, splice junction, and amino acid substitution variants in both &#x003b1;6 and &#x003b2;4 integrin have been described and would result in EB-PA [<a class="bk_pop" href="#ebj.REF.ruzzi.1997.2826">Ruzzi et al 1997</a>, <a class="bk_pop" href="#ebj.REF.gache.1998.914">Gache et al 1998</a>, <a class="bk_pop" href="#ebj.REF.l_pinard.2000.70">L&#x000e9;pinard et al 2000</a>, <a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>, <a class="bk_pop" href="#ebj.REF.masunaga.2015.61">Masunaga et al 2015</a>, <a class="bk_pop" href="#ebj.REF.menc_a.2016.269">Menc&#x000ed;a et al 2016</a>, <a class="bk_pop" href="#ebj.REF.masunaga.2017.160">Masunaga et al 2017</a>].</p><div id="ebj.COL17A1"><h4><i>COL17A1</i></h4><p><b>Gene structure.</b> The <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000494.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000494.3</a> encodes 1,497 amino acids in 56 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1125/#ebj.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> There is one alternatively spliced <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> variant [<a class="bk_pop" href="#ebj.REF.ruzzi.2001.182">Ruzzi et al 2001</a>].</p><p><b>Pathogenic variants.</b> Pathogenic variants in <i>COL17A1</i>, which encodes the collagen XVII protein, a component of the hemidesmosome, typically result in JEB generalized intermediate [<a class="bk_pop" href="#ebj.REF.gatalica.1997.352">Gatalica et al 1997</a>, <a class="bk_pop" href="#ebj.REF.pulkkinen.1999.1114">Pulkkinen et al 1999</a>, <a class="bk_pop" href="#ebj.REF.takizawa.2000a.312">Takizawa et al 2000a</a>, <a class="bk_pop" href="#ebj.REF.van_leusden.2001.887">van Leusden et al 2001</a>, <a class="bk_pop" href="#ebj.REF.pasmooij.2004.125">Pasmooij et al 2004</a>], although a few individuals with lethal JEB resulting from <i>COL17A1</i> pathogenic variants have been described [<a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>, <a class="bk_pop" href="#ebj.REF.murrell.2007.1772">Murrell et al 2007</a>]. All types of variants (including premature termination codon, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a>/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, splice junction, and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants) distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been described. The type and location of the variants and the response of the cells to the variants determines the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, which can range from mild to severe and in some cases lethal. Reversion to a normal phenotype has been described [<a class="bk_pop" href="#ebj.REF.pasmooij.2005.727">Pasmooij et al 2005</a>, <a class="bk_pop" href="#ebj.REF.pasmooij.2012.1374">Pasmooij et al 2012</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Collagen XVII, <a href="https://www.ncbi.nlm.nih.gov/protein/NP_000485.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000485.3</a>, (also known as BP180) has 1,497 amino acids and is composed of intracellular and extracellular domains separated by a transmembrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> that distinguishes collagen XVII from other collagen family members. The intracellular domain is localized within the basal keratinocyte; the ectodomain is localized outside the cell and serves as an association point with other components of the basement membrane zone. The carboxy-terminal half of collagen XVII, a stretch of 916 amino acids, consists of 15 collagen domains of variable length (15 to 242 amino acids) that are separated by short stretches of non-collagen sequences. The collagenous domains associate to form a homotrimeric triple helical segment of the molecule characteristic of all collagen family members.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Premature termination codon pathogenic variants that result in a <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> cause skin fragility, dental abnormalities, and alopecia usually found in individuals with JEB generalized intermediate. Other pathogenic variants may result in varying phenotypic severity. Although <i>COL17A1</i> variants do not usually result in lethality, several cases of a neonatal lethal <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> were described [<a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>, <a class="bk_pop" href="#ebj.REF.murrell.2007.1772">Murrell et al 2007</a>]. Pathogenic variants that affect the intracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> may result in a cleavage plane more consistent with EBS and be misleading in terms of diagnosis based on electron microscopy biopsy results. Pathogenic variants that affect the transmembrane domain may result in intracellular accumulation of collagen XVII protein. Although glycine substitutions in <i>COL17A1</i> have been described, no <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> variants resulting in skin fragility have been identified. Heterozygous carriers of a glycine substitution [<a class="bk_pop" href="#ebj.REF.nakamura.2006.333">Nakamura et al 2006</a>] or other <i>COL17A1</i> variants [<a class="bk_pop" href="#ebj.REF.murrell.2007.1772">Murrell et al 2007</a>] may exhibit dental enamel pitting and this characteristic may be diagnostic for <i>COL17A1</i> pathogenic variants in a family with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child [<a class="bk_pop" href="#ebj.REF.murrell.2007.1772">Murrell et al 2007</a>].</p></div><div id="ebj.ITGB4"><h4><i>ITGB4</i></h4><p><b>Gene structure.</b> The normal full-length <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> is encoded in 41 exons spanning 36 kb of the <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. The cDNA comprises 6,033 bp with an <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> of 5,469 nucleotides encoding 1,822 amino acids. Two <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants express different <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> of the protein [<a class="bk_pop" href="#ebj.REF.pulkkinen.1997c.823">Pulkkinen et al 1997c</a>]. The most common epidermal variant does not express <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 33. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/n/gene/eb-pa/#eb-pa.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 100 pathogenic variants spanning all of <i>ITGB4</i> have been described in individuals with EB-PA [<a class="bk_pop" href="#ebj.REF.pulkkinen.1997b.669">Pulkkinen et al 1997b</a>, <a class="bk_pop" href="#ebj.REF.pulkkinen.1997c.823">Pulkkinen et al 1997c</a>, <a class="bk_pop" href="#ebj.REF.pulkkinen.1998a.935">Pulkkinen et al 1998a</a>, <a class="bk_pop" href="#ebj.REF.pulkkinen.1998b.1376">Pulkkinen et al 1998b</a>, <a class="bk_pop" href="#ebj.REF.ashton.2001.408">Ashton et al 2001</a>, <a class="bk_pop" href="#ebj.REF.nakano.2001.618">Nakano et al 2001</a>, <a class="bk_pop" href="#ebj.REF.iacovacci.2003.716">Iacovacci et al 2003</a>, <a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>, <a class="bk_pop" href="#ebj.REF.masunaga.2015.61">Masunaga et al 2015</a>]. Pathogenic variants that cause premature termination codons on both alleles result in the most severe phenotypes, which are frequently lethal in the neonatal period. Other types of variants including amino acid substitutions and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants may result in a less severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ebj.REF.mellerio.1998.325">Mellerio et al 1998</a>, <a class="bk_pop" href="#ebj.REF.pulkkinen.1998b.1376">Pulkkinen et al 1998b</a>, <a class="bk_pop" href="#ebj.REF.chavanas.1999.2097">Chavanas et al 1999</a>, <a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>]. In one individual severe blistering without pyloric atresia was described from a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant in <i>ITGB4</i> [<a class="bk_pop" href="#ebj.REF.inoue.2000.1061">Inoue et al 2000</a>] and in another a homozygote with missense and PTC <i>ITGB4</i> variants [<a class="bk_pop" href="#ebj.REF.inoue.2000.1061">Inoue et al 2000</a>, <a class="bk_pop" href="#ebj.REF.jonkman.2000.227">Jonkman et al 2000</a>]. Few recurrent pathogenic variants have been described; however, the variant p.Cys61Tyr is common in individuals of Hispanic ancestry with JEB-PA in the US [<a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>]. See <a class="figpopup" href="/books/NBK1125/table/ebj.T.itgb4_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebjTitgb4pathogenicvariantsdiscusse" rid-ob="figobebjTitgb4pathogenicvariantsdiscusse">Table 3</a>.</p><div id="ebj.T.itgb4_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>ITGB4</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1125/table/ebj.T.itgb4_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebj.T.itgb4_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebj.T.itgb4_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ebj.T.itgb4_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ebj.T.itgb4_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ebj.T.itgb4_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.182G&#x0003e;A</td><td headers="hd_h_ebj.T.itgb4_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys61Tyr</td><td headers="hd_h_ebj.T.itgb4_pathogenic_variants_discusse_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000213.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000213<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_000204.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><u>NP_000204.3</u></a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Integrins associate in pairs containing one alpha and one beta chain. &#x003b1;6&#x003b2;4 integrin comprises one &#x003b1;6 and one &#x003b2;4 integrin protein from the integrin family of proteins and is a component of the hemidesmosomes of the epidermis. Within the hemidesmosome, &#x003b1;6&#x003b2;4 integrin forms attachments with collagen XVII to fulfill its role in the network of protein giving the epidermal strength and integrity and anchoring the epidermal cells to the underlying dermis through adhesion of the hemidesmosomes to the basement membrane. &#x003b1;6&#x003b2;4 integrin has also been shown to be involved in cell signaling and may play a role in carcinogenesis [<a class="bk_pop" href="#ebj.REF.chung.2004.32287">Chung et al 2004</a>, <a class="bk_pop" href="#ebj.REF.guo.2006.489">Guo et al 2006</a>, <a class="bk_pop" href="#ebj.REF.yoon.2006.2732">Yoon et al 2006</a>, <a class="bk_pop" href="#ebj.REF.folgiero.2007.1645">Folgiero et al 2007</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Null alleles may result in little or no protein seen with staining with anti-&#x003b1;6&#x003b2;4 integrin antibodies. Reduced staining was seen in some milder cases resulting from amino acid substitutions or splice junction variants.</p></div><div id="ebj.LAMA3"><h4><i>LAMA3</i></h4><p><b>Gene structure.</b> All of <i>LAMA3</i> is encoded in 76 exons spanning 318 kb on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 18q11.2. Transcript variants are produced by alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> (see <a class="figpopup" href="/books/NBK1125/table/ebj.T.lama3_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebjTlama3pathogenicvariantsdiscusse" rid-ob="figobebjTlama3pathogenicvariantsdiscusse">Table 4</a> and <a class="bk_pop" href="#ebj.REF.mclean.2003.2395">McLean et al [2003]</a>). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> information along with additional transcripts and protein <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>, see <a href="/books/NBK1125/#ebj.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Nonsense, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, and <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a>/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variants have been reported [<a class="bk_pop" href="#ebj.REF.nakano.2002a.41">Nakano et al 2002a</a>, <a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>]. Premature termination codon pathogenic variants on both alleles result in JEB generalized severe in most instances. A few mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with JEB with premature termination codon variants have been reported [<a class="bk_pop" href="#ebj.REF.nakano.2002a.41">Nakano et al 2002a</a>]. Amino acid substitutions and splicing variants may result in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ebj.REF.posteraro.1998.758">Posteraro et al 1998</a>, <a class="bk_pop" href="#ebj.REF.nakano.2002a.41">Nakano et al 2002a</a>]. Overlapping phenotypes in which pathogenic variants in <i>LAMA3</i> result in skin fragility with eye and laryngeal involvement may exist [<a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>, <a class="bk_pop" href="#ebj.REF.figueira.2007.163">Figueira et al 2007</a>].</p><div id="ebj.T.lama3_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>LAMA3</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1125/table/ebj.T.lama3_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebj.T.lama3_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebj.T.lama3_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ebj.T.lama3_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ebj.T.lama3_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ebj.T.lama3_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.151dupG&#x000a0;<sup>1</sup></td><td headers="hd_h_ebj.T.lama3_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val51GlyfsTer4</td><td headers="hd_h_ebj.T.lama3_pathogenic_variants_discusse_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000227.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000227<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/732170493" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000218<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_ebj.T.lama3_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1981C&#x0003e;T&#x000a0;<sup>2</sup></td><td headers="hd_h_ebj.T.lama3_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg661Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ebj.TF.4.1"><p class="no_margin">See <a href="#ebj.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</a>.</p></div></dd><dt>2. </dt><dd><div id="ebj.TF.4.2"><p class="no_margin">Cited by <a class="bk_pop" href="#ebj.REF.mcgrath.1996.781">McGrath et al [1996]</a> as c.1948C&#x0003e;T (p.Arg650Ter) without a reference sequence. Coordinates here from citation in OMIM <a href="https://omim.org/entry/600805" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">600805</a>, allelic variant 0.0002 with dbSNP identification of rs17852757, which gives the above HGVS coordinates for the reference sequence in this table.</p></div></dd></dl></div></div></div><div id="ebj.T.lama3_transcript_variants_and_prot" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>LAMA3</i> Transcript Variants and Protein Isoforms Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1125/table/ebj.T.lama3_transcript_variants_and_prot/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebj.T.lama3_transcript_variants_and_prot_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1" colspan="4" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;">Transcript Variants</th><th id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2" colspan="4" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;">Protein Isoforms</th></tr><tr><th headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1" id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Name(s)</th><th headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1" id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Accession #</th><th headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1" id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Length (nt)</th><th headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1" id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Total # Exons</th><th headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2" id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Name(s)</th><th headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2" id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Accession #</th><th headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2" id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Amino Acids (#)</th><th headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2" id="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Encoded by Exon #s&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2, 3a</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000227.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000227<wbr style="display:inline-block"></wbr>​.4</a></td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5,623</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">38</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b1;3a, 2, LAMA3a</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/protein/NP_000218.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000218<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1,724</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">39-76</td></tr><tr><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1, 3b1</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_198129.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_198129<wbr style="display:inline-block"></wbr>​.2</a>&#x000a0;<sup>2</sup></td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10,666</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">75</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b1;3b1, 1, LAM3b1</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/protein/NP_937762.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_937762<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3,333</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1-38 &#x00026; 40-76</td></tr><tr><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3, 3b2</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/732170490" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001127717<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10,498</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_1 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">74</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b1;3b2, 3, LAM3b2</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/protein/NP_001121189.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001121189<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3,277</td><td headers="hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_1_2 hd_h_ebj.T.lama3_transcript_variants_and_prot_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1-9, 11-38, &#x00026; 40-76</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">See <a href="https://www.ncbi.nlm.nih.gov/gene/3909" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>LAMA3</i></a>, <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> sequence <a href="https://www.ncbi.nlm.nih.gov/nuccore/NC_000018.10" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NC_000018<wbr style="display:inline-block"></wbr>​.10</a></p></div></dd><dt>1. </dt><dd><div id="ebj.TF.5.1"><p class="no_margin">Exon numbers based on <a class="bk_pop" href="#ebj.REF.mclean.2003.2395">McLean et al [2003]</a></p></div></dd><dt>2. </dt><dd><div id="ebj.TF.5.2"><p class="no_margin">Longest transcript; the <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> sequence of <i>LAMA3</i> should be sequenced for diagnostic purposes (<a class="figpopup" href="/books/NBK1125/table/ebj.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figebjTmoleculargenetictestingusedin" rid-ob="figobebjTmoleculargenetictestingusedin">Table 1</a>, footnote 8).</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> There are three <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> (&#x003b1;3a, &#x003b1;3b1, &#x003b1;3b2) produced by alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> (<a class="figpopup" href="/books/NBK1125/table/ebj.T.lama3_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebjTlama3pathogenicvariantsdiscusse" rid-ob="figobebjTlama3pathogenicvariantsdiscusse">Table 4</a>). Note that the shorter &#x003b1;3b2 isoform of 1,724 amino acids is encoded in 38 exons (exons 39-76 of <i>LAMA3</i>) and is unique in that <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 39 is expressed.</p><p>The laminin A3 protein associates with laminin B3 and C2 proteins to form the laminin 332 heterotrimer that comprises the anchoring fibrils in the epidermis. The anchoring fibrils hold the layers of the basal lamina together and form associations with collagen VII on the dermal side and plectin and &#x003b1;6&#x003b2;4 integrin in the hemidesmosomes on the epidermal side. This interaction allows the formation of the protein network of the epidermis, which results in a flexible and resilient barrier to resist trauma.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#ebj.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</a>. In all three genes (<i>LAMB3</i>, <i>LAMC2</i>, and <i>LAMA3</i>), amino acid substitutions, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants, and <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions and insertions may result in the formation of some partially functional protein that results in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Specific amino acid substitutions, such as replacement of cysteine residues, inhibit the formation of disulfide bonds, result in altered laminin 332 intra- and intermolecular associations, and may result in a more severe phenotype. On a skin biopsy studied with immunofluorescence, if synthesis of one of the proteins is disrupted, the staining for the other two proteins will usually also be affected.</p></div><div id="ebj.LAMB3"><h4><i>LAMB3</i></h4><p><b>Gene structure.</b> The normal <i>LAMB3</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> has an <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> of 3,516 nucleotides in 23 exons spanning 29 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1125/#ebj.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Nonsense, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, and <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a>/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variants have been reported [<a class="bk_pop" href="#ebj.REF.nakano.2002b.510">Nakano et al 2002b</a>, <a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>]. A few mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons with premature termination codon variants have been reported [<a class="bk_pop" href="#ebj.REF.pulkkinen.1998a.935">Pulkkinen et al 1998a</a>, <a class="bk_pop" href="#ebj.REF.nakano.2002a.41">Nakano et al 2002a</a>]. Amino acid substitutions and splicing variants may result in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ebj.REF.mellerio.1998.325">Mellerio et al 1998</a>, <a class="bk_pop" href="#ebj.REF.posteraro.1998.758">Posteraro et al 1998</a>, <a class="bk_pop" href="#ebj.REF.nakano.2002a.41">Nakano et al 2002a</a>]. The following <i>LAMB3</i> pathogenic variants, <a class="figpopup" href="/books/NBK1125/table/ebj.T.lamb3_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebjTlamb3pathogenicvariantsdiscusse" rid-ob="figobebjTlamb3pathogenicvariantsdiscusse">p.Arg635Ter</a>, <a class="figpopup" href="/books/NBK1125/table/ebj.T.lamb3_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebjTlamb3pathogenicvariantsdiscusse" rid-ob="figobebjTlamb3pathogenicvariantsdiscusse">p.Gln243Ter</a>, <a class="figpopup" href="/books/NBK1125/table/ebj.T.lamb3_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebjTlamb3pathogenicvariantsdiscusse" rid-ob="figobebjTlamb3pathogenicvariantsdiscusse">c.957ins77</a>, <a class="figpopup" href="/books/NBK1125/table/ebj.T.lamb3_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figebjTlamb3pathogenicvariantsdiscusse" rid-ob="figobebjTlamb3pathogenicvariantsdiscusse">p.Arg42Ter</a> are present in approximately 45% of individuals with H-JEB in the US [<a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>]. These pathogenic variants invariably result in premature termination codons and when found on both alleles result in JEB generalized severe.</p><div id="ebj.T.lamb3_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p><i>LAMB3</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1125/table/ebj.T.lamb3_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebj.T.lamb3_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.124C&#x0003e;T</td><td headers="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg42Ter</td><td headers="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=62868214" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000228<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/entrez/viewer.fcgi?db=protein&#x00026;id=62868215" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000219<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.727C&#x0003e;T</td><td headers="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln243Ter</td></tr><tr><td headers="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.957ins77</td><td headers="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu320Ter</td></tr><tr><td headers="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1903C&#x0003e;T</td><td headers="hd_h_ebj.T.lamb3_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg635Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The laminin B3 protein has 1,172 amino acids. It associates with laminin A3 and C2 proteins to form the laminin 332 heterotrimer that comprises the anchoring fibrils in the epidermis.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#ebj.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</a>. In all three genes (<i>LAMB3</i>, <i>LAMC2</i>, and <i>LAMA3</i>), amino acid substitutions, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants, and <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions and insertions may result in the formation of some partially functional protein that results in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Specific amino acid substitutions, such as replacement of cysteine residues, inhibit the formation of disulfide bonds, result in altered laminin 332 intra- and intermolecular associations, and may result in a more severe phenotype. On a skin biopsy studied with immunofluorescence, if synthesis of one of the proteins is disrupted, the staining for the other two proteins will usually also be affected. Reversion by <i>LAMB3</i> <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> to a normal phenotype has been described and has implications for treatment [<a class="bk_pop" href="#ebj.REF.pasmooij.2007.1240">Pasmooij et al 2007</a>].</p></div><div id="ebj.LAMC2"><h4><i>LAMC2</i></h4><p><b>Gene structure.</b> Two <i>LAMC2</i> transcript variants result from alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>. The longer <i>LAMC2</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> transcript <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_005562.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_005562.2</a> is expressed in the epidermis and encodes 1,193 amino acids in 23 exons spanning 55 kb. The shorter transcript variant, <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_018891.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_018891.2</a>, is expressed in the cerebral cortex, lung, and distal tubules of the kidney. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, transcript, and protein information, see <a href="/books/NBK1125/#ebj.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Nonsense, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, and <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a>/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variants have been reported [<a class="bk_pop" href="#ebj.REF.castiglia.2001.731">Castiglia et al 2001</a>, <a class="bk_pop" href="#ebj.REF.nakano.2002b.510">Nakano et al 2002b</a>, <a class="bk_pop" href="#ebj.REF.varki.2006.641">Varki et al 2006</a>]. Amino acid substitutions and splicing variants may result in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ebj.REF.posteraro.1998.758">Posteraro et al 1998</a>, <a class="bk_pop" href="#ebj.REF.castiglia.2001.731">Castiglia et al 2001</a>, <a class="bk_pop" href="#ebj.REF.nakano.2002a.41">Nakano et al 2002a</a>].</p><div id="ebj.T.lamc2_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p><i>LAMC2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1125/table/ebj.T.lamc2_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ebj.T.lamc2_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ebj.T.lamc2_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ebj.T.lamc2_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ebj.T.lamc2_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ebj.T.lamc2_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.283C&#x0003e;T</td><td headers="hd_h_ebj.T.lamc2_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg95Ter</td><td headers="hd_h_ebj.T.lamc2_pathogenic_variants_discusse_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_005562.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_005562<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_005553.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_005553<wbr style="display:inline-block"></wbr>​.2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The laminin C2 protein associates with laminins A3 and C2 to form the laminin 332 heterotrimer that makes up the anchoring fibrils in the epidermis.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#ebj.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</a>. In all three genes (<i>LAMB3</i>, <i>LAMC2</i>, and <i>LAMA3</i>), amino acid substitutions, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants, and <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions and insertions may result in the formation of some partially functional protein that results in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Specific amino acid substitutions, such as replacement of cysteine residues, inhibit the formation of disulfide bonds, result in altered laminin 332 intra- and intermolecular associations, and may result in a more severe phenotype. On a skin biopsy studied with immunofluorescence, if synthesis of one of the proteins is disrupted, the staining for the other two proteins will usually also be affected.</p></div></div></div><div id="ebj.References"><h2 id="_ebj_References_">References</h2><div id="ebj.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.almaani.2009.1094">Almaani N, Liu L, Dopping-Hepenstal PJ, Lovell PA, Lai-Cheong JE, Graham RM, Mellerio JE, McGrath JA. Autosomal dominant junctional epidermolysis bullosa. <span><span class="ref-journal">Br J Dermatol. </span>2009;<span class="ref-vol">160</span>:1094–7.</span> [<a href="/pubmed/19120338" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19120338</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.ashton.2001.408">Ashton GH, Sorelli P, Mellerio JE, Keane FM, Eady RA, McGrath JA. Alpha 6 beta 4 integrin abnormalities in junctional epidermolysis bullosa with pyloric atresia. <span><span class="ref-journal">Br J Dermatol. </span>2001;<span class="ref-vol">144</span>:408–14.</span> [<a href="/pubmed/11251584" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11251584</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.aumailley.2005.326">Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E, Jones JC, Kleinman HK, Marinkovich MP, Martin GR, Mayer U, Meneguzzi G, Miner JH, Miyazaki K, Patarroyo M, Paulsson M, Quaranta V, Sanes JR, Sasaki T, Sekiguchi K, Sorokin LM, Talts JF, Tryggvason K, Uitto J, Virtanen I, von der Mark K, Wewer UM, Yamada Y, Yurchenco PD. A simplified laminin nomenclature. <span><span class="ref-journal">Matrix Biol. </span>2005;<span class="ref-vol">24</span>:326–32.</span> [<a href="/pubmed/15979864" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15979864</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.azizkhan.2007.801">Azizkhan RG, Denyer JE, Mellerio JE, Gonz&#x000e1;lez R, Bacigalupo M, Kantor A, Passalacqua G, Palisson F, Lucky AW. Surgical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile. <span><span class="ref-journal">Int J Dermatol. </span>2007;<span class="ref-vol">46</span>:801–8.</span> [<a href="/pubmed/17651160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17651160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.barzegar.2013.1353">Barzegar M, Mozafari N, Kariminejad A, Asadikani Z, Ozoemena L, McGrath JA. A new homozygous nonsense mutation in LAMA3A underlying laryngo-onycho-cutaneous syndrome. <span><span class="ref-journal">Br J Dermatol. </span>2013;<span class="ref-vol">169</span>:1353–6.</span> [<a href="/pubmed/23869449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23869449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.bubier.2010.1819">Bubier JA, Sproule TJ, Alley LM, Webb CM, Fine JD, Roopenian DC, Sundberg JP. A mouse model of generalized non-Herlitz junctional epidermolysis bullosa. <span><span class="ref-journal">J Invest Dermatol. </span>2010;<span class="ref-vol">130</span>:1819–28.</span> [<a href="/pmc/articles/PMC3010368/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3010368</span></a>] [<a href="/pubmed/20336083" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20336083</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.capt.2005.530">Capt A, Spirito F, Guaguere E, Spadafora A, Ortonne JP, Meneguzzi G. Inherited junctional epidermolysis bullosa in the German Pointer: establishment of a large animal model. <span><span class="ref-journal">J Invest Dermatol. </span>2005;<span class="ref-vol">124</span>:530–5.</span> [<a href="/pubmed/15737193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15737193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.castiglia.2001.731">Castiglia D, Posteraro P, Spirito F, Pinola M, Angelo C, Puddu P, Meneguzzi G, Zambruno G. Novel mutations in the LAMC2 gene in non-Herlitz junctional epidermolysis bullosa: effects on laminin-5 assembly, secretion, and deposition. <span><span class="ref-journal">J Invest Dermatol. </span>2001;<span class="ref-vol">117</span>:731–9.</span> [<a href="/pubmed/11564184" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11564184</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.charlesworth.2003.1344">Charlesworth A, Gagnoux-Palacios L, Bonduelle M, Ortonne JP, De Raeve L, Meneguzzi G. Identification of a lethal form of epidermolysis bullosa simplex associated with a homozygous genetic mutation in plectin. <span><span class="ref-journal">J Invest Dermatol. </span>2003;<span class="ref-vol">121</span>:1344–8.</span> [<a href="/pubmed/14675180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14675180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.chavanas.1999.2097">Chavanas S, Gache Y, Vailly J, Kanitakis J, Pulkkinen L, Uitto J, Ortonne J, Meneguzzi G. Splicing modulation of integrin beta4 pre-mRNA carrying a branch point mutation underlies epidermolysis bullosa with pyloric atresia undergoing spontaneous amelioration with ageing. <span><span class="ref-journal">Hum Mol Genet. </span>1999;<span class="ref-vol">8</span>:2097–105.</span> [<a href="/pubmed/10484780" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10484780</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.chung.2004.32287">Chung J, Yoon SO, Lipscomb EA, Mercurio AM. The Met receptor and alpha 6 beta 4 integrin can function independently to promote carcinoma invasion. <span><span class="ref-journal">J Biol Chem. </span>2004;<span class="ref-vol">279</span>:32287–93.</span> [<a href="/pubmed/15161909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15161909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.cohn.2010.89">Cohn HI, Murrell DF. Laryngo-onycho-cutaneous syndrome. <span><span class="ref-journal">Dermatol Clin. </span>2010;<span class="ref-vol">28</span>:89–92.</span> [<a href="/pubmed/19945620" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19945620</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.cserhalmifriedman.2002.468">Cserhalmi-Friedman PB, Anyane-Yeboa K, Christiano AM. Paternal germline mosaicism in Herlitz junctional epidermolysis bullosa. <span><span class="ref-journal">Exp Dermatol. </span>2002;<span class="ref-vol">11</span>:468–70.</span> [<a href="/pubmed/12366701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12366701</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.cserhalmifriedman.1998.105">Cserhalmi-Friedman PB, Baden H, Burgeson RE, Christiano AM. Molecular basis of non-lethal junctional epidermolysis bullosa: identification of a 38 basepair insertion and a splice site mutation in exon 14 of the LAMB3 gene. <span><span class="ref-journal">Exp Dermatol. </span>1998;<span class="ref-vol">7</span>:105–11.</span> [<a href="/pubmed/9583749" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9583749</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.denyer.2010.257">Denyer JE. Wound management for children with epidermolysis bullosa. <span><span class="ref-journal">Dermatol Clin. </span>2010;<span class="ref-vol">28</span>:257–64.</span> [<a href="/pubmed/20447488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20447488</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.de_rosa.2013.1">De Rosa L, Carulli S, Cocchiarella F, Quaglino D, Enzo E, Franchini E, Giannetti A, De Santis G, Recchia A, Pellegrini G, De Luca M. Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa. <span><span class="ref-journal">Stem Cell Reports. </span>2013;<span class="ref-vol">2</span>:1–8.</span> [<a href="/pmc/articles/PMC3916757/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3916757</span></a>] [<a href="/pubmed/24511464" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24511464</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.di_nunzio.2008.1977">Di Nunzio F, Maruggi G, Ferrari S, Di Iorio E, Poletti V, Garcia M, Del Rio M, De Luca M, Larcher F, Pellegrini G, Mavilio F. Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors. <span><span class="ref-journal">Mol Ther. </span>2008;<span class="ref-vol">16</span>:1977–85.</span> [<a href="/pubmed/18813277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18813277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.du.2018.689">Du R, Dinckan N, Song X, Coban-Akdemir Z, Jhangiani SN, Guven Y, Aktoren O, Kayserili H, Petty LE, Muzny DM, Below JE, Boerwinkle E, Wu N, Gibbs RA, Posey JE, Lupski JR, Letra A, Uyguner ZO. Identification of likely pathogenic and known variants in TSPEAR, LAMB3, BCOR, and WNT10A in four Turkish families with tooth agenesis. <span><span class="ref-journal">Hum Genet. </span>2018;<span class="ref-vol">137</span>:689–703.</span> [<a href="/pmc/articles/PMC6165673/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6165673</span></a>] [<a href="/pubmed/30046887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30046887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.endo.2012.561">Endo M, Zoltick PW, Radu A, Jiang Q, Matsui C, Marinkovich PM, McGrath J, Tamai K, Uitto J, Flake AW. Early intra-amniotic gene transfer using lentiviral vector improves skin blistering phenotype in a murine model of Herlitz junctional epidermolysis bullosa. <span><span class="ref-journal">Gene Ther. </span>2012;<span class="ref-vol">19</span>:561–9.</span> [<a href="/pmc/articles/PMC6541916/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6541916</span></a>] [<a href="/pubmed/21938019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21938019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.fassihi.2005.71">Fassihi H, Wessagowit V, Ashton GH, Moss C, Ward R, Denyer J, Mellerio JE, McGrath JA. Complete paternal uniparental isodisomy of chromosome 1 resulting in Herlitz junctional epidermolysis bullosa. <span><span class="ref-journal">Clin Exp Dermatol. </span>2005;<span class="ref-vol">30</span>:71–4.</span> [<a href="/pubmed/15663509" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15663509</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.fewtrell.2006.959">Fewtrell MS, Allgrove J, Gordon I, Brain C, Atherton D, Harper J, Mellerio JE, Martinez AE. Bone mineralization in children with epidermolysis bullosa. <span><span class="ref-journal">Br J Dermatol. </span>2006;<span class="ref-vol">154</span>:959–62.</span> [<a href="/pubmed/16634901" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16634901</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.figueira.2007.163">Figueira EC, Crotty A, Challinor CJ, Coroneo MT, Murrell DF. Granulation tissue in the eyelid margin and conjunctiva in junctional epidermolysis bullosa with features of laryngo-onycho-cutaneous syndrome. <span><span class="ref-journal">Clin Experiment Ophthalmol. </span>2007;<span class="ref-vol">35</span>:163–6.</span> [<a href="/pubmed/17362460" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17362460</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.fine.1999">Fine JD, Bauer EA, McGuire J Moshell A, eds. <em>Epidermolysis Bullosa; Clinical Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry</em>. Baltimore, MD: Johns Hopkins University Press; 1999.</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.fine.2014.1103">Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, Marinkovich MP, Martinez AE, McGrath JA, Mellerio JE, Moss C, Murrell DF, Shimizu H, Uitto J, Woodley D, Zambruno G. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. <span><span class="ref-journal">J Am Acad Dermatol. </span>2014;<span class="ref-vol">70</span>:1103–26.</span> [<a href="/pubmed/24690439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24690439</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.fine.2004.651">Fine JD, Johnson LB, Weiner M, Stein A, Cash S, DeLeoz J, Devries DT, Suchindran C, et al.  Inherited epidermolysis bullosa and the risk of death from renal disease: experience of the National Epidermolysis Bullosa Registry. <span><span class="ref-journal">Am J Kidney Dis. </span>2004;<span class="ref-vol">44</span>:651–60.</span> [<a href="/pubmed/15384016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15384016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.folgiero.2007.1645">Folgiero V, Bachelder RE, Bon G, Sacchi A, Falcioni R, Mercurio AM. The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function. <span><span class="ref-journal">Cancer Res. </span>2007;<span class="ref-vol">67</span>:1645–52.</span> [<a href="/pubmed/17308105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17308105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.gache.1998.914">Gache Y, Romero-Graillet C, Spadafora A, L&#x000e9;pinard C, Descamps P, Bardon CB, Ortonne JP, Meneguzzi G. A novel homozygous mutation affecting integrin alpha6 in a case of junctional epidermolysis bullosa with pyloric atresia detected in utero by ultrasound examination. <span><span class="ref-journal">J Invest Dermatol. </span>1998;<span class="ref-vol">111</span>:914–6.</span> [<a href="/pubmed/9804362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9804362</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.gatalica.1997.352">Gatalica B, Pulkkinen L, Li K, Kuokkanen K, Ryyn&#x000e4;nen M, McGrath JA, Uitto J. Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">60</span>:352–65.</span> [<a href="/pmc/articles/PMC1712405/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1712405</span></a>] [<a href="/pubmed/9012408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9012408</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.goldschneider.2014.178">Goldschneider KR, Good J, Harrop E, Liossi C, Lynch-Jordan A, Martinez AE, Maxwell LG, Stanko-Lopp D, et al.  Pain care for patients with epidermolysis bullosa: best care practice guidelines. <span><span class="ref-journal">BMC Med. </span>2014;<span class="ref-vol">12</span>:178.</span> [<a href="/pmc/articles/PMC4190576/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4190576</span></a>] [<a href="/pubmed/25603875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25603875</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.gosty_ski.2014.98">Gosty&#x00144;ski A, Pasmooij AM, Jonkman MF. Successful therapeutic transplantation of revertant skin in epidermolysis bullosa. <span><span class="ref-journal">J Am Acad Dermatol. </span>2014;<span class="ref-vol">70</span>:98–101.</span> [<a href="/pubmed/24176523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24176523</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.gosty_ska.2016.94">Gosty&#x00144;ska KB, Yan Yuen W, Pasmooij AM, Stellingsma C, Pas HH, Lemmink H, Jonkman MF. Carriers with functional null mutations in LAMA3 have localized enamel abnormalities due to haploinsufficiency. <span><span class="ref-journal">Eur J Hum Genet. </span>2016;<span class="ref-vol">25</span>:94–9.</span> [<a href="/pmc/articles/PMC5159771/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5159771</span></a>] [<a href="/pubmed/27827380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27827380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.guo.2006.489">Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. <span><span class="ref-journal">Cell. </span>2006;<span class="ref-vol">126</span>:489–502.</span> [<a href="/pubmed/16901783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16901783</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.hammersen.2016.2150">Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, S&#x000f6;der S, Tardieu M, Metzler M, Bruckner-Tuderman L, Schneider H. Genotype, clinical course, and therapeutic decision making in 76 infants with severe generalized junctional epidermolysis bullosa. <span><span class="ref-journal">J Invest Dermatol. </span>2016;<span class="ref-vol">136</span>:2150–7.</span> [<a href="/pubmed/27375110" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27375110</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.hammersen.2015.921">Hammersen J, Hou J, W&#x000fc;nsche S, Brenner S, Winkler T, Schneider H. A new mouse model of junctional epidermolysis bullosa: the LAMB3 628G&#x0003e;A knockin mouse. <span><span class="ref-journal">J Invest Dermatol. </span>2015;<span class="ref-vol">135</span>:921–4.</span> [<a href="/pubmed/25350318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25350318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.hirsch.2017.327">Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, Scaglione D, Reichelt J, Klausegger A, Kneisz D, Romano O, Secone Seconetti A, Contin R, Enzo E, Jurman I, Carulli S, Jacobsen F, Luecke T, Lehnhardt M, Fischer M, Kueckelhaus M, Quaglino D, Morgante M, Bicciato S, Bondanza S, De Luca M. Regeneration of the entire human epidermis using transgenic stem cells. <span><span class="ref-journal">Nature. </span>2017;<span class="ref-vol">551</span>:327–32.</span> [<a href="/pmc/articles/PMC6283270/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6283270</span></a>] [<a href="/pubmed/29144448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29144448</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.huber.2002.185">Huber M, Floeth M, Borradori L, Sch&#x000e4;cke H, Rugg EL, Lane EB, Frenk E, Hohl D, Bruckner-Tuderman L. Deletion of the cytoplasmatic domain of BP180/collagen XVII causes a phenotype with predominant features of epidermolysis bullosa simplex. <span><span class="ref-journal">J Invest Dermatol. </span>2002;<span class="ref-vol">118</span>:185–92.</span> [<a href="/pubmed/11851893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11851893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.iacovacci.2003.716">Iacovacci S, Cicuzza S, Odorisio T, Silvestri E, Kayserili H, Zambruno G, Puddu P, D'Alessio M. Novel and recurrent mutations in the integrin beta 4 subunit gene causing lethal junctional epidermolysis bullosa with pyloric atresia. <span><span class="ref-journal">Exp Dermatol. </span>2003;<span class="ref-vol">12</span>:716–20.</span> [<a href="/pubmed/14705814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14705814</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.ida.2012.657">Ida JB, Livshitz I, Azizkhan RG, Lucky AW, Elluru RG. Upper airway complications of junctional epidermolysis bullosa. <span><span class="ref-journal">J Pediatr. </span>2012;<span class="ref-vol">160</span>:657–61.e1.</span> [<a href="/pubmed/22050875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22050875</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.igoucheva.2008.1476">Igoucheva O, Kelly A, Uitto J, Alexeev V. Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3-/- keratinocytes in vitro. <span><span class="ref-journal">J Invest Dermatol. </span>2008;<span class="ref-vol">128</span>:1476–86.</span> [<a href="/pmc/articles/PMC3357058/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3357058</span></a>] [<a href="/pubmed/18079746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18079746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.inoue.2000.1061">Inoue M, Tamai K, Shimizu H, Owaribe K, Nakama T, Hashimoto T, McGrath JA. A homozygous missense mutation in the cytoplasmic tail of beta4 integrin, G931D, that disrupts hemidesmosome assembly and underlies non-Herlitz junctional epidermolysis bullosa without pyloric atresia? <span><span class="ref-journal">J Invest Dermatol. </span>2000;<span class="ref-vol">114</span>:1061–4.</span> [<a href="/pubmed/10792571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10792571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.jiang.2005.xi">Jiang QJ, Uitto J. Animal models of epidermolysis bullosa--targets for gene therapy. <span><span class="ref-journal">J Invest Dermatol. </span>2005;<span class="ref-vol">124</span>:xi–xiii.</span> [<a href="/pubmed/15812910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15812910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.jonkman.2000.227">Jonkman MF, Schuur J, Dijk F, Heeres K, de Jong MC, van der Meer JB, Yancey KB, Pas HH. Inflammatory variant of epidermolysis bullosa acquisita with IgG autoantibodies against type VII collagen and laminin alpha3. <span><span class="ref-journal">Arch Dermatol. </span>2000;<span class="ref-vol">136</span>:227–31.</span> [<a href="/pubmed/10677099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10677099</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.kajbafzadeh.2010.1763">Kajbafzadeh AM, Elmi A, Mazaheri P, Talab SS, Jan D. Genitourinary involvement in epidermolysis bullosa: clinical presentations and therapeutic challenges. <span><span class="ref-journal">BJU Int. </span>2010;<span class="ref-vol">106</span>:1763–6.</span> [<a href="/pubmed/20477826" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20477826</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.kambham.2000.190">Kambham N, Tanji N, Seigle RL, Markowitz GS, Pulkkinen L, Uitto J, D'Agati VD. Congenital focal segmental glomerulosclerosis associated with beta4 integrin mutation and epidermolysis bullosa. <span><span class="ref-journal">Am J Kidney Dis. </span>2000;<span class="ref-vol">36</span>:190–6.</span> [<a href="/pubmed/10873890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10873890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.kellymancuso.2014.159">Kelly-Mancuso G, Kopelan B, Azizkhan RG, Lucky AW. Junctional epidermolysis bullosa incidence and survival: 5-year experience of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA) Nurse Educator. <span><span class="ref-journal">Pediatr Dermatol. </span>2014;<span class="ref-vol">31</span>:159–62.</span> [<a href="/pubmed/23721227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23721227</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.kim.2013.899">Kim JW, Seymen F, Lee KE, Ko J, Yildirim M, Tuna EB, Gencay K, Shin TJ, Kyun HK, Simmer JP, Hu JC. LAMB3 mutations causing autosomal dominant amelogenesis imperfecta. <span><span class="ref-journal">J Dent Res. </span>2013;<span class="ref-vol">92</span>:899–904.</span> [<a href="/pmc/articles/PMC3775375/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3775375</span></a>] [<a href="/pubmed/23958762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23958762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.kiritsi.2013.135">Kiritsi D, Has C, Bruckner-Tuderman L. Laminin 332 in junctional epidermolysis bullosa. <span><span class="ref-journal">Cell Adh Migr. </span>2013;<span class="ref-vol">7</span>:135–41.</span> [<a href="/pmc/articles/PMC3544777/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3544777</span></a>] [<a href="/pubmed/23076207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23076207</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.kirkham.2000.377">Kirkham J, Robinson C, Strafford SM, Shore RC, Bonass WA, Brookes SJ, Wright JT. The chemical composition of tooth enamel in junctional epidermolysis bullosa. <span><span class="ref-journal">Arch Oral Biol. </span>2000;<span class="ref-vol">45</span>:377–86.</span> [<a href="/pubmed/10739859" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10739859</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.kowalewski.2016.1375">Kowalewski C, Bremer J, Gostynski A, Wertheim-Tysarowska K, Wozniak K, Bal J, Jonkman MF, Pasmooij AM. Amelioration of junctional epidermolysis bullosa due to exon skipping. <span><span class="ref-journal">Br J Dermatol. </span>2016;<span class="ref-vol">174</span>:1375–9.</span> [<a href="/pubmed/26708078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26708078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.kr_mer.2010.303">Kr&#x000e4;mer SM. Oral care and dental management for patients with epidermolysis bullosa. <span><span class="ref-journal">Dermatol Clin. </span>2010;<span class="ref-vol">28</span>:303–9.</span> [<a href="/pubmed/20447495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20447495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.kr_mer.2012.1">Kr&#x000e4;mer SM, Serrano MC, Zillmann G, G&#x000e1;lvez P, Araya I, Yanine N, Carrasco-Labra A, Oliva P, Brignardello-Petersen R, Villanueva J, et al.  Oral health care for patients with epidermolysis bullosa--best clinical practice guidelines. <span><span class="ref-journal">Int J Paediatr Dent. </span>2012;<span class="ref-vol">22</span> Suppl 1:1–35.</span> [<a href="/pubmed/22937908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22937908</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.laracorrales.2010.238">Lara-Corrales I, Mellerio JE, Martinez AE, Green A, Lucky AW, Azizkhan RG, Murrell DF, Agero AL, Kantor PF, Pope E. Dilated cardiomyopathy in epidermolysis bullosa: a retrospective, multicenter study. <span><span class="ref-journal">Pediatr Dermatol. </span>2010;<span class="ref-vol">27</span>:238–43.</span> [<a href="/pubmed/20609141" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20609141</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.lee.2015.90">Lee KE, Ko J, Le CG, Shin TJ, Hyun HK, Lee SH, Kim JW. Novel LAMB3 mutations cause non-syndromic amelogenesis imperfecta with variable expressivity. <span><span class="ref-journal">Clin Genet. </span>2015;<span class="ref-vol">87</span>:90–2.</span> [<a href="/pmc/articles/PMC4302247/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4302247</span></a>] [<a href="/pubmed/24494736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24494736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.l_pinard.2000.70">L&#x000e9;pinard C, Descamps P, Meneguzzi G, Blanchet-Bardon C, Germain DP, Larget-Piet L, Beringue F, Berchel C, Muller F, Dumez Y. Prenatal diagnosis of pyloric atresia-junctional epidermolysis bullosa syndrome in a fetus not known to be at risk. <span><span class="ref-journal">Prenat Diagn. </span>2000;<span class="ref-vol">20</span>:70–5.</span> [<a href="/pubmed/10701857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10701857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.lincoln.2018">Lincoln V, Cogan J, Hou Y, Hirsch M, Hao M, Alexeev V, De Luca M, De Rosa L, Bauer JW, Woodley DT, Chen M. 2018 Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa. Proc Natl Acad Sci U S A. 10;115(28): [<a href="/pmc/articles/PMC6048497/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6048497</span></a>] [<a href="/pubmed/29946029" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29946029</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.lucky.2018.188">Lucky AW, Dagaonkar N, Lammers K, Husami A, Kissell D, Zhang K. A comprehensive next-generation sequencing assay for the diagnosis of epidermolysis bullosa. <span><span class="ref-journal">Pediatr Dermatol. </span>2018;<span class="ref-vol">35</span>:188–197.</span> [<a href="/pubmed/29334134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29334134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.lucky.2007.809">Lucky AW, Pfendner E, Pillay E, Paskel J, Weiner M, Palisson F. Psychosocial aspects of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile. <span><span class="ref-journal">Int J Dermatol. </span>2007;<span class="ref-vol">46</span>:809–14.</span> [<a href="/pubmed/17651161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17651161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.masunaga.2015.61">Masunaga T, Niizeki H, Yasuda F, Yoshida K, Amagai M, Ishiko A. Splicing abnormality of integrin &#x003b2;4 gene (ITGB4) due to nucleotide substitutions far from splice site underlies pyloric atresia-junctional epidermolysis bullosa syndrome. <span><span class="ref-journal">J Dermatol Sci. </span>2015;<span class="ref-vol">78</span>:61–6.</span> [<a href="/pubmed/25728941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25728941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.masunaga.2017.160">Masunaga T, Ogawa J, Akiyama M, Nishikawa T, Shimizu H, Ishiko A. Compound heterozygosity for novel splice site mutations of ITGA6 in lethal junctional epidermolysis bullosa with pyloric atresia. <span><span class="ref-journal">J Dermatol. </span>2017;<span class="ref-vol">44</span>:160–6.</span> [<a href="/pubmed/27607025" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27607025</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.mavilio.2006.1397">Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, Maruggi G, Ferrari G, Provasi E, Bonini C, Capurro S, Conti A, Magnoni C, Giannetti A, De Luca M. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. <span><span class="ref-journal">Nat Med. </span>2006;<span class="ref-vol">12</span>:1397–402.</span> [<a href="/pubmed/17115047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17115047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.mcgrath.1999.314">McGrath JA, Ashton GH, Mellerio JE, Salas-Alanis JC, Swensson O, McMillan JR, Eady RA. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations. <span><span class="ref-journal">J Invest Dermatol. </span>1999;<span class="ref-vol">113</span>:314–21.</span> [<a href="/pubmed/10469327" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10469327</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.mcgrath.1996.781">McGrath JA, Kivirikko S, Ciatti S, Moss C, Christiano AM, Uitto J. A recurrent homozygous nonsense mutation within the LAMA3 gene as a cause of Herlitz junctional epidermolysis bullosa in patients of Pakistani ancestry: evidence for a founder effect. <span><span class="ref-journal">J Invest Dermatol. </span>1996;<span class="ref-vol">106</span>:781–4.</span> [<a href="/pubmed/8618022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8618022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.mclean.2003.2395">McLean WH, Irvine AD, Hamill KJ, Whittock NV, Coleman-Campbell CM, Mellerio JE, Ashton GS, Dopping-Hepenstal PJ, Eady RA, Jamil T, Phillips R, Shabbir SG, Haroon TS, Khurshid K, Moore JE, Page B, Darling J, Atherton DJ, Van Steensel MA, Munro CS, Smith FJ, McGrath JA. An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome. <span><span class="ref-journal">Hum Mol Genet. </span>2003;<span class="ref-vol">12</span>:2395–409.</span> [<a href="/pubmed/12915477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12915477</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.mellerio.1998.325">Mellerio JE, Eady RA, Atherton DJ, Lake BD, McGrath JA. E210K mutation in the gene encoding the beta3 chain of laminin-5 (LAMB3) is predictive of a phenotype of generalized atrophic benign epidermolysis bullosa. <span><span class="ref-journal">Br J Dermatol. </span>1998;<span class="ref-vol">139</span>:325–31.</span> [<a href="/pubmed/9767254" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9767254</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.melo.2014.725">Melo SP, Lisowski L, Bashkirova E, Zhen HH, Chu K, Keene DR, Marinkovich MP, Kay MA, Oro AE. Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant. <span><span class="ref-journal">Mol Ther. </span>2014;<span class="ref-vol">22</span>:725–33.</span> [<a href="/pmc/articles/PMC3982486/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3982486</span></a>] [<a href="/pubmed/24390279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24390279</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.menc_a.2016.269">Menc&#x000ed;a &#x000c1;, Garc&#x000ed;a M, Garc&#x000ed;a E. Llames, Charlesworth A, de Lucas R, Vicente A, Trujillo-Tiebas MJ, Coto P, Costa M, Vera &#x000c1;, L&#x000f3;pez-Pesta&#x000f1;a A, Murillas R, Meneguzzi G, Jorcano JL, Conti CJ, Esc&#x000e1;mez Toledano MJ, del R&#x000ed;o Nechaevsky M. Identification of two rare and novel large deletions in ITGB4 gene causing epidermolysis bullosa with pyloric atresia. <span><span class="ref-journal">Exp Dermatol. </span>2016;<span class="ref-vol">25</span>:269–74.</span> [<a href="/pubmed/26739954" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26739954</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.micheloni.2004.796">Micheloni A, De Luca N, Tadini G, Zambruno G, D'Alessio M. Intracellular degradation of beta4 integrin in lethal junctional epidermolysis bullosa with pyloric atresia. <span><span class="ref-journal">Br J Dermatol. </span>2004;<span class="ref-vol">151</span>:796–802.</span> [<a href="/pubmed/15491419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15491419</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.montaudi_.2016.117">Montaudi&#x000e9; H, Chiaverini C, Sbidian E, Charlesworth A, Lacour JP. Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2016;<span class="ref-vol">11</span>:117.</span> [<a href="/pmc/articles/PMC4992553/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4992553</span></a>] [<a href="/pubmed/27544590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27544590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.m_hle.2006.1665">M&#x000fc;hle C, Neuner A, Park J, Pacho F, Jiang Q, Waddington SN, Schneider H. Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease. <span><span class="ref-journal">Gene Ther. </span>2006;<span class="ref-vol">13</span>:1665–76.</span> [<a href="/pubmed/16871230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16871230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.murrell.2007.1772">Murrell DF, Pasmooij AM, Pas HH, Marr P, Klingberg S, Pfendner E, Uitto J, Sadowski S, Collins F, Widmer R, Jonkman MF. Retrospective diagnosis of fatal BP180-deficient non-Herlitz junctional epidermolysis bullosa suggested by immunofluorescence (IF) antigen-mapping of parental carriers bearing enamel defects. <span><span class="ref-journal">J Invest Dermatol. </span>2007;<span class="ref-vol">127</span>:1772–5.</span> [<a href="/pubmed/17344927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17344927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.nagata.1997.445">Nagata M, Iwasaki T, Masuda H, Shimizu H. Non-lethal junctional epidermolysis bullosa in a dog. <span><span class="ref-journal">Br J Dermatol. </span>1997;<span class="ref-vol">137</span>:445–9.</span> [<a href="/pubmed/9349347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9349347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.nakamura.2006.333">Nakamura H, Sawamura D, Goto M, Nakamura H, Kida M, Ariga T, Sakiyama Y, Tomizawa K, Mitsui H, Tamaki K, Shimizu H. Analysis of the COL17A1 in non-Herlitz junctional epidermolysis bullosa and amelogenesis imperfecta. <span><span class="ref-journal">Int J Mol Med. </span>2006;<span class="ref-vol">18</span>:333–7.</span> [<a href="/pubmed/16820943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16820943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.nakano.2002a.41">Nakano A, Chao SC, Pulkkinen L, Murrell D, Bruckner-Tuderman L, Pfendner E, Uitto J. Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes. <span><span class="ref-journal">Hum Genet. </span>2002a;<span class="ref-vol">110</span>:41–51.</span> [<a href="/pubmed/11810295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11810295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.nakano.2002b.510">Nakano A, Lestringant GG, Paperna T, Bergman R, Gershoni R, Frossard P, Kanaan M, Meneguzzi G, Richard G, Pfendner E, Uitto J, Pulkkinen L, Sprecher E. Junctional epidermolysis bullosa in the Middle East: clinical and genetic studies in a series of consanguineous families. <span><span class="ref-journal">J Am Acad Dermatol. </span>2002b;<span class="ref-vol">46</span>:510–6.</span> [<a href="/pubmed/11907499" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11907499</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.nakano.2000.493">Nakano A, Pfendner E, Hashimoto I, Uitto J. Herlitz junctional epidermolysis bullosa: novel and recurrent mutations in the LAMB3 gene and the population carrier frequency. <span><span class="ref-journal">J Invest Dermatol. </span>2000;<span class="ref-vol">115</span>:493–8.</span> [<a href="/pubmed/11023379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11023379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.nakano.2001.618">Nakano A, Pulkkinen L, Murrell D, Rico J, Lucky AW, Garzon M, Stevens CA, Robertson S, Pfendner E, Uitto J. Epidermolysis bullosa with congenital pyloric atresia: novel mutations in the beta 4 integrin gene (ITGB4) and genotype/phenotype correlations. <span><span class="ref-journal">Pediatr Res. </span>2001;<span class="ref-vol">49</span>:618–26.</span> [<a href="/pubmed/11328943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11328943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.natsuga.2010.137">Natsuga K, Shinkuma S, Nishie W, Shimizu H. Animal models of epidermolysis bullosa. <span><span class="ref-journal">Dermatol Clin. </span>2010;<span class="ref-vol">28</span>:137–42.</span> [<a href="/pubmed/19945627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19945627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.ortizurda.2003.1099">Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. <span><span class="ref-journal">Gene Ther. </span>2003;<span class="ref-vol">10</span>:1099–104.</span> [<a href="/pubmed/12808440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12808440</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.osborn.2013.1151">Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, DeFeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, Blazar BR, Tolar J. TALEN-based gene correction for epidermolysis bullosa. <span><span class="ref-journal">Mol Ther. </span>2013;<span class="ref-vol">21</span>:1151–9.</span> [<a href="/pmc/articles/PMC3677309/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3677309</span></a>] [<a href="/pubmed/23546300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23546300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pasmooij.2012.1374">Pasmooij AM, Nijenhuis M, Brander R, Jonkman MF. Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations. <span><span class="ref-journal">J Invest Dermatol. </span>2012;<span class="ref-vol">132</span>:1374–83.</span> [<a href="/pubmed/22318390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22318390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pasmooij.2007.1240">Pasmooij AM, Pas HH, Bolling MC, Jonkman MF. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. <span><span class="ref-journal">J Clin Invest. </span>2007;<span class="ref-vol">117</span>:1240–8.</span> [<a href="/pmc/articles/PMC1857245/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1857245</span></a>] [<a href="/pubmed/17476356" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17476356</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pasmooij.2005.727">Pasmooij AM, Pas HH, Deviaene FC, Nijenhuis M, Jonkman MF. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. <span><span class="ref-journal">Am J Hum Genet. </span>2005;<span class="ref-vol">77</span>:727–40.</span> [<a href="/pmc/articles/PMC1271383/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1271383</span></a>] [<a href="/pubmed/16252234" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16252234</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pasmooij.2004.125">Pasmooij AM, van Zalen S, Nijenhuis AM, Kloosterhuis AJ, Zuiderveen J, Jonkman MF, Pas HH. A very mild form of non-Herlitz junctional epidermolysis bullosa: BP180 rescue by outsplicing of mutated exon 30 coding for the COL15 domain. <span><span class="ref-journal">Exp Dermatol. </span>2004;<span class="ref-vol">13</span>:125–8.</span> [<a href="/pubmed/15009107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15009107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pertica.2010.751">Pertica G, Riva J, Strillacci MG, Cozzi MC, Longeri M, Polli M. Prevalence of inherited junctional epidermolysis bullosa in German shorthaired pointers bred in Italy. <span><span class="ref-journal">Vet Rec. </span>2010;<span class="ref-vol">167</span>:751–2.</span> [<a href="/pubmed/21257512" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21257512</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pfendner.2001.483">Pfendner E, Uitto J, Fine JD. Epidermolysis bullosa carrier frequencies in the US population. <span><span class="ref-journal">J Invest Dermatol. </span>2001;<span class="ref-vol">116</span>:483–4.</span> [<a href="/pubmed/11231335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11231335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pfendner.2007.781">Pfendner EG, Bruckner A, Conget P, Mellerio J, Palisson F, Lucky AW. Basic science of epidermolysis bullosa and diagnostic and molecular characterization: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile. <span><span class="ref-journal">Int J Dermatol. </span>2007;<span class="ref-vol">46</span>:781–94.</span> [<a href="/pubmed/17651158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17651158</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pope.2012.904">Pope E, Lara-Corrales I, Mellerio J, Martinez A, Schultz G, Burrell R, Goodman L, Coutts P, Wagner J, Allen U, Sibbald G. A consensus approach to wound care in epidermolysis bullosa. <span><span class="ref-journal">J Am Acad Dermatol. </span>2012;<span class="ref-vol">67</span>:904–17.</span> [<a href="/pmc/articles/PMC3655403/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3655403</span></a>] [<a href="/pubmed/22387035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22387035</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.posteraro.2004.639">Posteraro P, De Luca N, Meneguzzi G, El Hachem M, Angelo C, Gobello T, Tadini G, Zambruno G, Castiglia D. Laminin-5 mutational analysis in an Italian cohort of patients with junctional epidermolysis bullosa. <span><span class="ref-journal">J Invest Dermatol. </span>2004;<span class="ref-vol">123</span>:639–48.</span> [<a href="/pubmed/15373767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15373767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.posteraro.1998.758">Posteraro P, Sorvillo S, Gagnoux-Palacios L, Angelo C, Paradisi M, Meneguzzi G, Castiglia D, Zambruno G. Compound heterozygosity for an out-of-frame deletion and a splice site mutation in the LAMB3 gene causes nonlethal junctional epidermolysis bullosa. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>1998;<span class="ref-vol">243</span>:758–64.</span> [<a href="/pubmed/9501007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9501007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.poulter.2014.132">Poulter JA, El-Sayed W, Shore RC, Kirkham J, Inglehearn CF, Mighell AJ. Whole-exome sequencing, without prior linkage, identifies a mutation in LAMB3 as a cause of dominant hypoplastic amelogenesis imperfecta. <span><span class="ref-journal">Eur J Hum Genet. </span>2014;<span class="ref-vol">22</span>:132–5.</span> [<a href="/pmc/articles/PMC3865405/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3865405</span></a>] [<a href="/pubmed/23632796" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23632796</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pulkkinen.1998a.935">Pulkkinen L, Bruckner-Tuderman L, August C, Uitto J. Compound heterozygosity for missense (L156P) and nonsense (R554X) mutations in the beta4 integrin gene (ITGB4) underlies mild, nonlethal phenotype of epidermolysis bullosa with pyloric atresia. <span><span class="ref-journal">Am J Pathol. </span>1998a;<span class="ref-vol">152</span>:935–41.</span> [<a href="/pmc/articles/PMC1858243/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1858243</span></a>] [<a href="/pubmed/9546354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9546354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pulkkinen.1997a.611">Pulkkinen L, Bullrich F, Czarnecki P, Weiss L, Uitto J. Maternal uniparental disomy of chromosome 1 with reduction to homozygosity of the LAMB3 locus in a patient with Herlitz junctional epidermolysis bullosa. <span><span class="ref-journal">Am J Hum Genet. </span>1997a;<span class="ref-vol">61</span>:611–9.</span> [<a href="/pmc/articles/PMC1715967/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715967</span></a>] [<a href="/pubmed/9326326" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9326326</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pulkkinen.1997b.669">Pulkkinen L, Kimonis VE, Xu Y, Spanou EN, McLean WH, Uitto J. Homozygous alpha6 integrin mutation in junctional epidermolysis bullosa with congenital duodenal atresia. <span><span class="ref-journal">Hum Mol Genet. </span>1997b;<span class="ref-vol">6</span>:669–74.</span> [<a href="/pubmed/9158140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9158140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pulkkinen.1997c.823">Pulkkinen L, Kurtz K, Xu Y, Bruckner-Tuderman L, Uitto J. Genomic organization of the integrin beta 4 gene (ITGB4): a homozygous splice-site mutation in a patient with junctional epidermolysis bullosa associated with pyloric atresia. <span><span class="ref-journal">Lab Invest. </span>1997c;<span class="ref-vol">76</span>:823–33.</span> [<a href="/pubmed/9194858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9194858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pulkkinen.1999.1114">Pulkkinen L, Marinkovich MP, Tran HT, Lin L, Herron GS, Uitto J. Compound heterozygosity for novel splice site mutations in the BPAG2/COL17A1 gene underlies generalized atrophic benign epidermolysis bullosa. <span><span class="ref-journal">J Invest Dermatol. </span>1999;<span class="ref-vol">113</span>:1114–8.</span> [<a href="/pubmed/10636730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10636730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pulkkinen.1995.77">Pulkkinen L, McGrath JA, Christiano AM, Uitto J. Detection of sequence variants in the gene encoding the beta 3 chain of laminin 5 (LAMB3). <span><span class="ref-journal">Hum Mutat. </span>1995;<span class="ref-vol">6</span>:77–84.</span> [<a href="/pubmed/7550237" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7550237</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.pulkkinen.1998b.1376">Pulkkinen L, Rouan F, Bruckner-Tuderman L, Wallerstein R, Garzon M, Brown T, Smith L, Carter W, Uitto J. Novel ITGB4 mutations in lethal and nonlethal variants of epidermolysis bullosa with pyloric atresia: missense versus nonsense. <span><span class="ref-journal">Am J Hum Genet. </span>1998b;<span class="ref-vol">63</span>:1376–87.</span> [<a href="/pmc/articles/PMC1377547/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377547</span></a>] [<a href="/pubmed/9792864" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9792864</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.puvabanditsin.1997.359">Puvabanditsin S, Garrow E, Samransamraujkit R, Lopez LA, Lambert WC. Epidermolysis bullosa associated with congenital localized absence of skin, fetal abdominal mass, and pyloric atresia. <span><span class="ref-journal">Pediatr Dermatol. </span>1997;<span class="ref-vol">14</span>:359–62.</span> [<a href="/pubmed/9336805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9336805</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.robbins.2001.5193">Robbins PB, Lin Q, Goodnough JB, Tian H, Chen X, Khavari PA. In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2001;<span class="ref-vol">98</span>:5193–8.</span> [<a href="/pmc/articles/PMC33186/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC33186</span></a>] [<a href="/pubmed/11296269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11296269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.ruzzi.1997.2826">Ruzzi L, Gagnoux-Palacios L, Pinola M, Belli S, Meneguzzi G, D'Alessio M, Zambruno G. A homozygous mutation in the integrin alpha6 gene in junctional epidermolysis bullosa with pyloric atresia. <span><span class="ref-journal">J Clin Invest. </span>1997;<span class="ref-vol">99</span>:2826–31.</span> [<a href="/pmc/articles/PMC508131/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC508131</span></a>] [<a href="/pubmed/9185503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9185503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.ruzzi.2001.182">Ruzzi L, Pas H, Posteraro P, Mazzanti C, Didona B, Owaribe K, Meneguzzi G, Zambruno G, Castiglia D, D'Alessio M. A homozygous nonsense mutation in type XVII collagen gene (COL17A1) uncovers an alternatively spliced mRNA accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa. <span><span class="ref-journal">J Invest Dermatol. </span>2001;<span class="ref-vol">116</span>:182–7.</span> [<a href="/pubmed/11168815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11168815</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.salvestrini.2008.585">Salvestrini C, McGrath JA, Ozoemena L, Husain K, Buhamrah E, Sabery N, Leichtner A, Rufo PA, Perez-Atayde A, Orteu CH, Torrente F, Heuschkel RB, Thomson MA, Murch SH. Desquamative enteropathy and pyloric atresia without skin disease caused by a novel intracellular beta4 integrin mutation. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>2008;<span class="ref-vol">47</span>:585–91.</span> [<a href="/pubmed/18955862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.shinkuma.2011.412">Shinkuma S, McMillan JR, Shimizu H. Ultrastructure and molecular pathogenesis of epidermolysis bullosa. <span><span class="ref-journal">Clin Dermatol. </span>2011;<span class="ref-vol">29</span>:412–9.</span> [<a href="/pubmed/21679868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21679868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.spirito.2006.769">Spirito F, Capt A, Del Rio M, Larcher F, Guaguere E, Danos O, Meneguzzi G. Sustained phenotypic reversion of junctional epidermolysis bullosa dog keratinocytes: establishment of an immunocompetent animal model for cutaneous gene therapy. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2006;<span class="ref-vol">339</span>:769–78.</span> [<a href="/pubmed/16316622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16316622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.spirito.2002.684">Spirito F, Charlesworth A, Linder K, Ortonne JP, Baird J, Meneguzzi G. Animal models for skin blistering conditions: absence of laminin 5 causes hereditary junctional mechanobullous disease in the Belgian horse. <span><span class="ref-journal">J Invest Dermatol. </span>2002;<span class="ref-vol">119</span>:684–91.</span> [<a href="/pubmed/12230513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12230513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.stellingsma.2011.405">Stellingsma C, Dijkstra PU, Dijkstra J, Duipmans JC, Jonkman MF, Dekker R. Restrictions in oral functions caused by oral manifestations of epidermolysis bullosa. <span><span class="ref-journal">Eur J Dermatol. </span>2011;<span class="ref-vol">21</span>:405–9.</span> [<a href="/pubmed/21609900" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21609900</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.takizawa.2000a.312">Takizawa Y, Hiraoka Y, Takahashi H, Ishiko A, Yasuraoka I, Hashimoto I, Aiso S, Nishikawa T, Shimizu H. Compound heterozygosity for a point mutation and a deletion located at splice acceptor sites in the LAMB3 gene leads to generalized atrophic benign epidermolysis bullosa. <span><span class="ref-journal">J Invest Dermatol. </span>2000a;<span class="ref-vol">115</span>:312–6.</span> [<a href="/pubmed/10951252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10951252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.takizawa.2000b.307">Takizawa Y, Pulkkinen L, Chao SC, Nakajima H, Nakano Y, Shimizu H, Uitto J. Mutation report: complete paternal uniparental isodisomy of chromosome 1: a novel mechanism for Herlitz junctional epidermolysis bullosa. <span><span class="ref-journal">J Invest Dermatol. </span>2000b;<span class="ref-vol">115</span>:307–11.</span> [<a href="/pubmed/10951251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10951251</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.tolar.2013.562">Tolar J, Xia L, Lees CJ, Riddle M, McElroy A, Keene DR, Lund TC, Osborn MJ, Marinkovich MP, Blazar BR, Wagner JE. Keratinocytes from induced pluripotent stem cells in junctional epidermolysis bullosa. <span><span class="ref-journal">J Invest Dermatol. </span>2013;<span class="ref-vol">133</span>:562–5.</span> [<a href="/pmc/articles/PMC3514565/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3514565</span></a>] [<a href="/pubmed/22931927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22931927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.umegakiarao.2014.264ra164">Umegaki-Arao N, Pasmooij AM, Itoh M, Cerise JE, Guo Z, Levy B, Gosty&#x00144;ski A, Rothman LR, Jonkman MF, Christiano AM. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa. <span><span class="ref-journal">Sci Transl Med. </span>2014;<span class="ref-vol">6</span>:264ra164.</span> [<a href="/pubmed/25429057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25429057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.van_leusden.2001.887">van Leusden MR, Pas HH, Gedde-Dahl T Jr, Sonnenberg A, Jonkman MF. Truncated typeXVII collagen expression in a patient with non-Herlitz junctional epidermolysis bullosa caused by a homozygous splice-site mutation. <span><span class="ref-journal">Lab Invest. </span>2001;<span class="ref-vol">81</span>:887–94.</span> [<a href="/pubmed/11406649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11406649</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.varki.2006.641">Varki R, Sadowski S, Pfendner E, Uitto J. Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:641–52.</span> [<a href="/pmc/articles/PMC2564586/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564586</span></a>] [<a href="/pubmed/16473856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16473856</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.wallerstein.2000.286">Wallerstein R, Klein ML, Genieser N, Pulkkinen L, Uitto J. Epidermolysis bullosa, pyloric atresia, and obstructive uropathy: a report of two case reports with molecular correlation and clinical management. <span><span class="ref-journal">Pediatr Dermatol. </span>2000;<span class="ref-vol">17</span>:286–9.</span> [<a href="/pubmed/10990577" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10990577</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.wang.2015.e0116514">Wang X, Zhao Y, Yang Y, Qin M. Novel ENAM and LAMB3 mutations in Chinese families with hypoplastic amelogenesis imperfecta. <span><span class="ref-journal">PLoS One. </span>2015;<span class="ref-vol">10</span>:e0116514.</span> [<a href="/pmc/articles/PMC4358960/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4358960</span></a>] [<a href="/pubmed/25769099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25769099</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.yan.2007.307">Yan EG, Paris JJ, Ahluwalia J, Lane AT, Bruckner AL. Treatment decision-making for patients with the Herlitz subtype of junctional epidermolysis bullosa. <span><span class="ref-journal">J Perinatol. </span>2007;<span class="ref-vol">27</span>:307–11.</span> [<a href="/pubmed/17363907" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17363907</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.yoon.2006.2732">Yoon SO, Shin S, Lipscomb EA. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. <span><span class="ref-journal">Cancer Res. </span>2006;<span class="ref-vol">66</span>:2732–9.</span> [<a href="/pubmed/16510594" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16510594</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.yuen.2013.93">Yuen WY, Huizinga J, Jonkman MF. Punch grafting of chronic ulcers in patients with laminin-332-deficient, non-Herlitz junctional epidermolysis bullosa. <span><span class="ref-journal">J Am Acad Dermatol. </span>2013;<span class="ref-vol">68</span>:93–7.</span> [<a href="/pubmed/22633040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22633040</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.yuen.2011.780">Yuen WY, Jonkman MF. Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: report of 7 cases and a review of the literature. <span><span class="ref-journal">J Am Acad Dermatol. </span>2011;<span class="ref-vol">65</span>:780–9.</span> [<a href="/pubmed/21624701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21624701</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ebj.REF.yuen.2012.695">Yuen WY, Pasmooij AM, Stellingsma C, Jonkman MF. Enamel defects in carriers of a novel LAMA3 mutation underlying epidermolysis bullosa. <span><span class="ref-journal">Acta Derm Venereol. </span>2012;<span class="ref-vol">92</span>:695–6.</span> [<a href="/pubmed/22434185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22434185</span></a>]</div></li></ul></div></div><div id="ebj.Chapter_Notes"><h2 id="_ebj_Chapter_Notes_">Chapter Notes</h2><div id="ebj.Author_Notes"><h3>Author Notes</h3><p>Web: <a href="http://www.genedx.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.genedx.com</a></p><p>Web: <a href="http://www.cincinnatichildrens.org/eb-center" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cincinnatichildrens.org/eb-center</a></p></div><div id="ebj.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>20 December 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 January 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 February 2008 (me) Review posted live</div></li><li class="half_rhythm"><div>10 May 2007 (egp) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1125</span><span class="label">PMID: <a href="/pubmed/20301304" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301304</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/joubert/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/jh/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1125&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1125/?report=reader">PubReader</a></li><li><a href="/books/NBK1125/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1125" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1125" style="display:none" title="Cite this Page"><div class="bk_tt">Pfendner EG, Lucky AW. Junctional Epidermolysis Bullosa. 2008 Feb 22 [Updated 2018 Dec 20]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1125/pdf/Bookshelf_NBK1125.pdf">PDF version of this page</a> (700K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ebj.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ebj.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ebj.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ebj.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ebj.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ebj.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ebj.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ebj.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ebj.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ebj.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ebj.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5339[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PLEC</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3909[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">LAMA3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1308[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">COL17A1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3691[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ITGB4</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3918[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">LAMC2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3655[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ITGA6</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3914[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">LAMB3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1125+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1481252" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1481252" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1481252" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1481252" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301336" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Epidermolysis Bullosa with Pyloric Atresia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Epidermolysis Bullosa with Pyloric Atresia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pfendner EG, Lucky AW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301481" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophic Epidermolysis Bullosa</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophic Epidermolysis Bullosa<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pfendner EG, Lucky AW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301543" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Epidermolysis Bullosa Simplex</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Epidermolysis Bullosa Simplex<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pfendner EG, Bruckner AL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26937547" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Kindler Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Kindler Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Youssefian L, Vahidnezhad H, Uitto J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24027798" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Erwin A, Balwani M, Desnick RJ, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301304" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301304" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0417dadde08911692de252">Junctional Epidermolysis Bullosa - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Junctional Epidermolysis Bullosa - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:15:55-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CAD20E040C2110000000004F201E6&amp;ncbi_session=CE8CAD20E0417DA1_1266SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1125%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1125&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1125/&amp;ncbi_pagename=Junctional Epidermolysis Bullosa - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CAD20E0417DA1_1266SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>